CN112500338A - 化合物及其用于调节血红蛋白的用途 - Google Patents
化合物及其用于调节血红蛋白的用途 Download PDFInfo
- Publication number
- CN112500338A CN112500338A CN202010996640.8A CN202010996640A CN112500338A CN 112500338 A CN112500338 A CN 112500338A CN 202010996640 A CN202010996640 A CN 202010996640A CN 112500338 A CN112500338 A CN 112500338A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- optionally substituted
- group
- ring
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 86
- 108010054147 Hemoglobins Proteins 0.000 title abstract description 13
- 102000001554 Hemoglobins Human genes 0.000 title abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 70
- 229910052717 sulfur Inorganic materials 0.000 claims description 163
- 125000005842 heteroatom Chemical group 0.000 claims description 144
- 229910052757 nitrogen Inorganic materials 0.000 claims description 132
- 229910052739 hydrogen Inorganic materials 0.000 claims description 96
- 239000001257 hydrogen Substances 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000000623 heterocyclic group Chemical group 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 70
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 52
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 50
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 239000000651 prodrug Chemical group 0.000 claims description 43
- 229940002612 prodrug Drugs 0.000 claims description 43
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical group 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 208000007056 sickle cell anemia Diseases 0.000 claims description 6
- 108010016797 Sickle Hemoglobin Proteins 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 3
- 229910014284 N-O Inorganic materials 0.000 claims description 2
- 229910014335 N—O Inorganic materials 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 239000000543 intermediate Substances 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 7
- 238000006213 oxygenation reaction Methods 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 112
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- -1 chiral cholesterol) Chemical class 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 47
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000012043 crude product Substances 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 20
- 229910001868 water Inorganic materials 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 201000010099 disease Diseases 0.000 description 16
- 238000002953 preparative HPLC Methods 0.000 description 16
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 16
- 239000012267 brine Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- DGXAGETVRDOQFP-UHFFFAOYSA-N 2,6-dihydroxybenzaldehyde Chemical compound OC1=CC=CC(O)=C1C=O DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000002198 insoluble material Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001503 aryl iodides Chemical class 0.000 description 4
- 238000006254 arylation reaction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- CLADBSZPHROUKB-UHFFFAOYSA-N 2-methoxy-5-(methoxymethoxy)pyridine-4-carbaldehyde Chemical compound COCOC1=CN=C(OC)C=C1C=O CLADBSZPHROUKB-UHFFFAOYSA-N 0.000 description 3
- VPYYBRWSCLINST-UHFFFAOYSA-N 5-hydroxy-2-(2-methoxyethoxy)pyridine-4-carbaldehyde Chemical compound COCCOC1=CC(C=O)=C(O)C=N1 VPYYBRWSCLINST-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229910020667 PBr3 Inorganic materials 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- XAMUHLXTZRUZDR-RGMNGODLSA-N [(2s)-piperidin-2-yl]methanol;hydrochloride Chemical compound Cl.OC[C@@H]1CCCCN1 XAMUHLXTZRUZDR-RGMNGODLSA-N 0.000 description 3
- PXKSXINFHADHPS-LLVKDONJSA-N [(3R)-3-(hydroxymethyl)morpholin-4-yl]-phenylmethanone Chemical compound OC[C@@H]1COCCN1C(=O)C1=CC=CC=C1 PXKSXINFHADHPS-LLVKDONJSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 230000003281 allosteric effect Effects 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 3
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XEHBFIRKVXTKKV-UHFFFAOYSA-N 2-(2-methoxyethoxy)-5-(methoxymethoxy)pyridine Chemical compound COCCOC1=CC=C(OCOC)C=N1 XEHBFIRKVXTKKV-UHFFFAOYSA-N 0.000 description 2
- NYDZWFBXOVCAIM-AWEZNQCLSA-N 2-[[(2s)-1-(benzenesulfonyl)pyrrolidin-2-yl]methoxy]-6-hydroxybenzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCC2)S(=O)(=O)C=2C=CC=CC=2)=C1C=O NYDZWFBXOVCAIM-AWEZNQCLSA-N 0.000 description 2
- OTNHCDMTINHDPR-INIZCTEOSA-N 2-[[(2s)-1-benzoylpiperidin-2-yl]methoxy]-6-hydroxybenzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCCC2)C(=O)C=2C=CC=CC=2)=C1C=O OTNHCDMTINHDPR-INIZCTEOSA-N 0.000 description 2
- AOMVIQXGKMTHAH-HNNXBMFYSA-N 2-[[(2s)-1-benzoylpyrrolidin-2-yl]methoxy]-6-hydroxybenzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCC2)C(=O)C=2C=CC=CC=2)=C1C=O AOMVIQXGKMTHAH-HNNXBMFYSA-N 0.000 description 2
- SXAADVVBQKBOHZ-HNNXBMFYSA-N 2-[[(3s)-4-benzoylmorpholin-3-yl]methoxy]-6-hydroxybenzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCOC2)C(=O)C=2C=CC=CC=2)=C1C=O SXAADVVBQKBOHZ-HNNXBMFYSA-N 0.000 description 2
- UXKRQWMPDCGRKY-AWEZNQCLSA-N 2-hydroxy-6-[[(2s)-1-(2-propan-2-ylpyrazole-3-carbonyl)pyrrolidin-2-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C(=O)N1[C@H](COC=2C(=C(O)C=CC=2)C=O)CCC1 UXKRQWMPDCGRKY-AWEZNQCLSA-N 0.000 description 2
- TWOOAJJERQIUND-ZDUSSCGKSA-N 2-hydroxy-6-[[(2s)-1-(pyridine-2-carbonyl)pyrrolidin-2-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCC2)C(=O)C=2N=CC=CC=2)=C1C=O TWOOAJJERQIUND-ZDUSSCGKSA-N 0.000 description 2
- AWTCNJQMMIGYMR-ZDUSSCGKSA-N 2-hydroxy-6-[[(2s)-1-pyridin-3-ylsulfonylpyrrolidin-2-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCC2)S(=O)(=O)C=2C=NC=CC=2)=C1C=O AWTCNJQMMIGYMR-ZDUSSCGKSA-N 0.000 description 2
- JWDZEPQEQCIVJH-UHFFFAOYSA-N 2-methoxy-5-(methoxymethoxy)pyridine Chemical compound COCOC1=CC=C(OC)N=C1 JWDZEPQEQCIVJH-UHFFFAOYSA-N 0.000 description 2
- MDMKGAHIENKPLC-UHFFFAOYSA-N 5-(methoxymethoxy)-1h-pyridin-2-one Chemical compound COCOC1=CC=C(O)N=C1 MDMKGAHIENKPLC-UHFFFAOYSA-N 0.000 description 2
- GVXOLOOMUXOIDK-UHFFFAOYSA-N 5-(methoxymethoxy)-2-phenylmethoxypyridine Chemical compound N1=CC(OCOC)=CC=C1OCC1=CC=CC=C1 GVXOLOOMUXOIDK-UHFFFAOYSA-N 0.000 description 2
- QZANZECZJMGHBS-UHFFFAOYSA-N 5-hydroxy-2-(2-methoxyethoxy)pyridine-3-carbaldehyde Chemical compound COCCOC1=NC=C(O)C=C1C=O QZANZECZJMGHBS-UHFFFAOYSA-N 0.000 description 2
- GRJJLRLFOQLVKR-UHFFFAOYSA-N 5-hydroxy-2-methoxypyridine-4-carbaldehyde Chemical compound COC1=CC(C=O)=C(O)C=N1 GRJJLRLFOQLVKR-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- ZIXSELYHQFHZIN-NSHDSACASA-N OC[C@H]1N(CCCC1)C(=O)C=1C(=NC=CC=1)C Chemical compound OC[C@H]1N(CCCC1)C(=O)C=1C(=NC=CC=1)C ZIXSELYHQFHZIN-NSHDSACASA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DQJZSCNPZKLJIE-LBPRGKRZSA-N [(2S)-2-(hydroxymethyl)piperidin-1-yl]-(6-methylpyridin-3-yl)methanone Chemical compound OC[C@H]1N(CCCC1)C(=O)C=1C=NC(=CC=1)C DQJZSCNPZKLJIE-LBPRGKRZSA-N 0.000 description 2
- CYZQZPAOQDMGII-NSHDSACASA-N [(2S)-2-(hydroxymethyl)piperidin-1-yl]-pyridin-3-ylmethanone Chemical compound OC[C@H]1N(CCCC1)C(=O)C=1C=NC=CC=1 CYZQZPAOQDMGII-NSHDSACASA-N 0.000 description 2
- VDRGQWKLTZSRAY-JTQLQIEISA-N [(2s)-1-(benzenesulfonyl)pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 VDRGQWKLTZSRAY-JTQLQIEISA-N 0.000 description 2
- OKNQDLVTQQTEPR-VIFPVBQESA-N [(2s)-1-pyridin-3-ylsulfonylpyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1S(=O)(=O)C1=CC=CN=C1 OKNQDLVTQQTEPR-VIFPVBQESA-N 0.000 description 2
- RGIJNYKDGHSPHP-LBPRGKRZSA-N [(2s)-2-(hydroxymethyl)piperidin-1-yl]-phenylmethanone Chemical compound OC[C@@H]1CCCCN1C(=O)C1=CC=CC=C1 RGIJNYKDGHSPHP-LBPRGKRZSA-N 0.000 description 2
- OHRXCHZLUAFHFJ-JTQLQIEISA-N [(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-(2-propan-2-ylpyrazol-3-yl)methanone Chemical compound CC(C)N1N=CC=C1C(=O)N1[C@H](CO)CCC1 OHRXCHZLUAFHFJ-JTQLQIEISA-N 0.000 description 2
- BAVMVXYQHCAUQS-NSHDSACASA-N [(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-phenylmethanone Chemical compound OC[C@@H]1CCCN1C(=O)C1=CC=CC=C1 BAVMVXYQHCAUQS-NSHDSACASA-N 0.000 description 2
- NZBNPPHCLHPBES-VIFPVBQESA-N [(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-pyridin-2-ylmethanone Chemical compound OC[C@@H]1CCCN1C(=O)C1=CC=CC=N1 NZBNPPHCLHPBES-VIFPVBQESA-N 0.000 description 2
- MTZRTAISCOCAMI-JTQLQIEISA-N [(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-pyridin-3-ylmethanone Chemical compound OC[C@@H]1CCCN1C(=O)C1=CC=CN=C1 MTZRTAISCOCAMI-JTQLQIEISA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002829 nitrogen Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- NZBUCABTIWJWAN-UHFFFAOYSA-N tetrabromomethane;triphenylphosphane Chemical compound BrC(Br)(Br)Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NZBUCABTIWJWAN-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- WXSGQHKHUYTJNB-UHFFFAOYSA-N 2,6-dimethoxybenzaldehyde Chemical compound COC1=CC=CC(OC)=C1C=O WXSGQHKHUYTJNB-UHFFFAOYSA-N 0.000 description 1
- VHGXVUHPAQXAJM-UHFFFAOYSA-N 2-(2-methoxyethoxy)-5-(methoxymethoxy)pyridine-4-carbaldehyde Chemical compound COCCOC1=CC(C=O)=C(OCOC)C=N1 VHGXVUHPAQXAJM-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- JLFHXNINERBPLZ-HNNXBMFYSA-N 2-hydroxy-6-[[(2s)-1-(2-methylpyridine-3-carbonyl)piperidin-2-yl]methoxy]benzaldehyde Chemical compound CC1=NC=CC=C1C(=O)N1[C@H](COC=2C(=C(O)C=CC=2)C=O)CCCC1 JLFHXNINERBPLZ-HNNXBMFYSA-N 0.000 description 1
- RYLYOEVKMYTDQA-INIZCTEOSA-N 2-hydroxy-6-[[(2s)-1-(6-methylpyridine-3-carbonyl)piperidin-2-yl]methoxy]benzaldehyde Chemical compound C1=NC(C)=CC=C1C(=O)N1[C@H](COC=2C(=C(O)C=CC=2)C=O)CCCC1 RYLYOEVKMYTDQA-INIZCTEOSA-N 0.000 description 1
- DIXJEEIWNGTEBR-HNNXBMFYSA-N 2-hydroxy-6-[[(2s)-1-(pyridine-3-carbonyl)piperidin-2-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCCC2)C(=O)C=2C=NC=CC=2)=C1C=O DIXJEEIWNGTEBR-HNNXBMFYSA-N 0.000 description 1
- LAEUDKTWJROGLP-AWEZNQCLSA-N 2-hydroxy-6-[[(2s)-1-(pyridine-3-carbonyl)pyrrolidin-2-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCC2)C(=O)C=2C=NC=CC=2)=C1C=O LAEUDKTWJROGLP-AWEZNQCLSA-N 0.000 description 1
- USYDBTWWZXXXES-AWEZNQCLSA-N 2-hydroxy-6-[[(2s)-1-(pyridine-4-carbonyl)pyrrolidin-2-yl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OC[C@H]2N(CCC2)C(=O)C=2C=CN=CC=2)=C1C=O USYDBTWWZXXXES-AWEZNQCLSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- HNTZKNJGAFJMHQ-UHFFFAOYSA-N 2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC=CC=C1C(O)=O HNTZKNJGAFJMHQ-UHFFFAOYSA-N 0.000 description 1
- ZIHRJZBCLMMKTC-UHFFFAOYSA-N 2-propan-2-ylpyrazole-3-carboxylic acid Chemical compound CC(C)N1N=CC=C1C(O)=O ZIHRJZBCLMMKTC-UHFFFAOYSA-N 0.000 description 1
- LKBKDKVMHWPZDB-UHFFFAOYSA-N 6-methoxypyridin-3-ol Chemical compound COC1=CC=C(O)C=N1 LKBKDKVMHWPZDB-UHFFFAOYSA-N 0.000 description 1
- RZOKQIPOABEQAM-UHFFFAOYSA-N 6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=N1 RZOKQIPOABEQAM-UHFFFAOYSA-N 0.000 description 1
- VKPWAEVWZUALPZ-UHFFFAOYSA-N 6-phenylmethoxypyridin-3-ol Chemical compound N1=CC(O)=CC=C1OCC1=CC=CC=C1 VKPWAEVWZUALPZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BDHBKIXJCKPABP-RFVHGSKJSA-N Cl.OC[C@@H]1COCCN1C(=O)c1ccccc1 Chemical compound Cl.OC[C@@H]1COCCN1C(=O)c1ccccc1 BDHBKIXJCKPABP-RFVHGSKJSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 229910003202 NH4 Inorganic materials 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ATRVYEBQKJUJJH-KRWDZBQOSA-N OC1=C(C=O)C(=CC=C1)OC[C@H]1N(CCCC1)CC1=CN=C(C=C1)C Chemical compound OC1=C(C=O)C(=CC=C1)OC[C@H]1N(CCCC1)CC1=CN=C(C=C1)C ATRVYEBQKJUJJH-KRWDZBQOSA-N 0.000 description 1
- CCXQDFPQVRMGFB-HNNXBMFYSA-N OC1=C(C=O)C(OC[C@H]2N(CC3=CC=NC=C3)CCC2)=CC=C1 Chemical compound OC1=C(C=O)C(OC[C@H]2N(CC3=CC=NC=C3)CCC2)=CC=C1 CCXQDFPQVRMGFB-HNNXBMFYSA-N 0.000 description 1
- FZDPUISDPSIHNS-HNNXBMFYSA-N OC1=C(C=O)C(OC[C@H]2N(CC3=CN=CC=C3)CCC2)=CC=C1 Chemical compound OC1=C(C=O)C(OC[C@H]2N(CC3=CN=CC=C3)CCC2)=CC=C1 FZDPUISDPSIHNS-HNNXBMFYSA-N 0.000 description 1
- XASIOGAUPYXIAU-INIZCTEOSA-N OC1=C(C=O)C(OC[C@H]2N(CC3=CN=CC=C3)CCCC2)=CC=C1 Chemical compound OC1=C(C=O)C(OC[C@H]2N(CC3=CN=CC=C3)CCCC2)=CC=C1 XASIOGAUPYXIAU-INIZCTEOSA-N 0.000 description 1
- 229910004727 OSO3H Inorganic materials 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229910006080 SO2X Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- UHPWEJZFGHHEJD-JTQLQIEISA-N [(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-pyridin-4-ylmethanone Chemical compound OC[C@@H]1CCCN1C(=O)C1=CC=NC=C1 UHPWEJZFGHHEJD-JTQLQIEISA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) Substances [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-aminopropionic acid Natural products NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical class BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical class OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000007347 radical substitution reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- PZTAGFCBNDBBFZ-VIFPVBQESA-N tert-butyl (2s)-2-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1CO PZTAGFCBNDBBFZ-VIFPVBQESA-N 0.000 description 1
- AIQSXVGBMCJQAG-MRVPVSSYSA-N tert-butyl (3r)-3-(hydroxymethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1CO AIQSXVGBMCJQAG-MRVPVSSYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical class C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- ZKEFILOOQGVKNY-UHFFFAOYSA-N triphenylphosphane;dihydrobromide Chemical compound Br.Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 ZKEFILOOQGVKNY-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
在此提供了适合作为血红蛋白的调节剂的化合物和药物组合物,用于制备它们的方法和中间体,以及在治疗血红蛋白介导的失调和受益于组织和/或细胞加氧的失调中使用它们的方法。
Description
本申请是中国申请号为201480015944.4、发明名称为“化合物及其用于调节血红蛋白的用途”且申请日为2014年3月10日的专利申请(PCT申请号为PCT/US2014/022769)的分案申请。
发明领域
本发明提供了适合作为血红蛋白的变构调节剂的化合物和药物组合物,用于制备它们的方法和中间体,以及在治疗血红蛋白介导的失调和受益于组织和/或细胞加氧的失调中使用它们的方法。
本领域现状
镰状细胞疾病是红血细胞的一种障碍,特别是发现于非洲和地中海血统者之中。镰状细胞疾病的基础发现于镰状血红蛋白(HbS),它相对于血红蛋白(Hb)的普遍肽序列包含点突变。
血红蛋白(Hb)将氧分子自肺部向全身的组织和器官运输。血红蛋白通过构象变化结合并且释放氧。镰状血红蛋白(HbS)包含点突变,其中谷氨酸被缬氨酸替换,允许HbS变得容易聚合以给出其特征为镰刀形状的包含HbS的红血细胞。这些镰状细胞还比正常红血细胞更具有刚性,并且它们对弹性的缺乏可能导致血管的阻塞。US 7,160,910披露了如下化合物,所述化合物是血红蛋白的变构调节剂。然而,对如下的另外的治疗剂存在需要,所述治疗剂可以治疗Hb或异常Hb(例如HbS)介导的失调。
发明概述
本发明总体上涉及适合作为血红蛋白的变构调节剂的化合物和药物组合物。在一些方面,本发明涉及用于治疗血红蛋白介导的失调和受益于组织和/或细胞加氧的失调的方法。
在本发明的某些方面,提供了具有化学式(A)的化合物:
或其互变异构体,或其各自药学上可接受的盐或其药学上可接受的盐,其中
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该-L1L2R3是α或β位取代的;
其中Z和-CV1V2H连接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
并且R3、B和C是如下定义的。
在一个情况下,
R3是C1-C6烷基、C3-C8环烷基、C1-C6烷氧基、C3-C8环烷氧基、或-NR1R2;
每个R1和R2独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-10元杂环或5-10元杂芳基,该杂环或杂芳基各自包含高达5个环杂原子,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中每个烷基、环烷基、杂环、芳基或杂芳基被任选取代,或R1和R2与它们附接的氮原子一起形成任选取代的4-7元杂环;
环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;并且
环C是任选取代的C6-C10芳基或任选取代的包含1-3个氮原子或N的氧化形式的5-10元杂芳基,其中某些优选的取代基包括OH、卤素、C1-C6烷氧基、C3-C6环烷氧基或O-R,其中R是前药部分,其中该C1-C6烷氧基任选被1-5个卤素取代。
在另一个情况下,
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基,和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中某些优选的取代基包括OH、卤素、C1-C6烷氧基、C3-C6环烷氧基或O-R,其中R是前药部分,其中该C1-C6烷氧基任选地被1-5个卤素取代;并且
R19是氢或前药部分R。
在本发明的某些方面,提供了具有化学式(II)的化合物:
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C1-C6烷基、C3-C8环烷基、C1-C6烷氧基、C3-C8环烷氧基、或-NR1R2;
每个R1和R2独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-10元杂环或5-10元杂芳基,该杂环或杂芳基各自包含高达5个环杂原子,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中每个烷基、环烷基、杂环、芳基或杂芳基被任选取代,或R1和R2与它们附接的氮原子一起形成任选取代的4-7元杂环;
L是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该-LCOR3是α或β位取代的;
环C是任选取代的C6-C10芳基或任选取代的包含1-3个氮原子或N的氧化形式的5-10元杂芳基;
其中Z和-CV1V2H连接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R4是OH、卤素、C1-C6烷氧基、C3-C6环烷氧基或O-R,其中R是前药部分,其中该C1-C6烷氧基任选地被1-5个卤素取代;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
在本发明的某些方面,提供了具有化学式(IV)的化合物:
其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
每个Y和Z独立地是(CR10R11)e、O、S、SO、SO2、或NR10;e是1至4,优选1;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该-L1L2R3是α或β位取代的;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,它们各自任选地被1-4个以下项取代:卤素、氧代、-OR2、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
R2是氢或前药部分R;并且
其中Z和-CV1V2H附接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
在一个实施例中,环b经由氮原子连接到L1或L2。在另一个实施例中,R3经由氮原子连接到L2。
在本发明的另外的方面,提供了包括在此所述的任何化合物以及至少一种药学上可接受的赋形剂的组合物。
在本发明的仍另外的方面,提供了用于增加受试者体内的血红蛋白S的氧亲和力的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物或组合物。
在本发明的另外的方面,提供了用于治疗与镰状细胞性贫血相关的缺氧的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物或组合物。
发明详述
定义
必须注意,除非上下文另外明确指示,否则如在此和所附权利要求中所使用,单数形式“一个/一种(a/an)”和“该”包括复数指示物。因此,例如,提及“溶剂”包括多种此类溶剂。
如在此使用的,术语“包含”(comprising或comprises)旨在意指这些组合物和方法包括列举的元素,但不排除其他。当用以定义组合物和方法时,“基本上由其组成”应意指排除对于说明目的的组合具有任一重要意义的其他元素。因此,基本上由如在此定义的元素组成的组合物或工艺将不排除不会实质上影响所要求的发明的基本特征和新颖特征的其他材料或步骤。“由……组成”应意指排除多于痕量元素的其他成分和实质性方法步骤。由这些连接词各自所界定的实施例在本发明的范围内。
除非另外指明,本说明书和权利要求书中使用的表达成分的量、反应条件等等的所有数值应被理解为在所有情况中被术语“约”修饰。因此,除非相反地说明,以下说明书和附加的权利要求中设定的数值参数是近似值。每一个数值参数至少应该按照报告的有效数字的数量以及通过应用普通的舍入技术来解释。当在数值名称例如温度、时间、量、以及浓度(包括范围)之前使用时,术语“约”指示可以按(+)或(-)10%、5%或1%变化的近似值。
如此处使用的,当在基团之前使用时,Cm-Cn例如C1-C12、C1-C8、或C1-C6是指包含m至n个碳原子的基团。
术语“烷氧基”是指-O-烷基。环烷氧基是指-O-环烷基。
术语“烷基”是指具有从1至30个碳原子(即,C1-C30烷基)或1至22个碳原子(即,C1-C22烷基)、1至8个碳原子(即,C1-C8烷基)、或1至4个碳原子的单价饱和脂肪族烃基基团。通过举例,此术语包括直链和支链烃基基团例如甲基(CH3-)、乙基(CH3CH2-)、n-丙基(CH3CH2CH2-)、异丙基((CH3)2CH-)、n-丁基(CH3CH2CH2CH2-)、异丁基((CH3)2CHCH2-)、仲丁基((CH3)(CH3CH2)CH-)、t-丁基((CH3)3C-)、n-戊基(CH3CH2CH2CH2CH2-)、以及新戊基((CH3)3CCH2-)。
术语“芳基”是指具有6-10个环碳原子的单价、芳香族单-或双环。芳基的实例包括苯基以及萘基。该缩合环可以是或可以不是芳香族,其条件是附接点是在芳香族碳原子处。例如,并且没有限制,以下是芳基基团:
术语“-CO2H酯”是指-CO2H基团和醇之间形成的酯,优选地脂肪醇。一个优选实例包括-CO2RE,其中RE是任选地被氨基基团取代的烷基或芳基基团。
术语“手性部分”是指是手性的部分。这样一个部分可以具有一个或多个不对称中心。优选地,该手性部分是对映异构性富集的,并且更优选地是单一对映异构体。手性部分的非限制实例包括手性羧酸、手性胺、手性氨基酸(例如天然发生的氨基酸)、手性醇(包括手性胆固醇)等等。
术语“环烷基”是指具有3-12个环碳原子的单价的,优选地饱和的烃基单-、二-、或三环的环。而环烷基优选地是指饱和的烃基环,如在此使用的,它也包括包含1-2个碳-碳双键的环。环烷基的非限制实例包括环丙基、环丁基、环戊基、环己基、环庚基、金刚烷基(adamentyl)等等。这些缩合环可以是或可以不是非芳香族烃基环,其条件是附接点是在环烷基碳原子处。例如,并且没有限制,以下是环烷基基团:
术语“卤素”是指F、Cl、Br、和/或I。
术语“杂芳基”是指具有2-16个环碳原子和1-8个环杂原子的单价、芳香族单-、二-、或三环的环,这些环杂原子优选地选自N、O、S、和P以及N、S、和P的氧化形式,其条件是该环包含至少5个环原子。杂芳基的非限制性实例包括呋喃、咪唑、噁二唑、噁唑、吡啶、喹啉等等。这些缩合环可以是或可以不是包含杂原子的芳香族环,其条件是附接点是杂芳基原子。例如,并且没有限制,以下是杂芳基基团:
术语“杂环基”或杂环是指包含2-12个环碳原子和1-8个环杂原子的非芳香族、单-、二-、或三环的环,这些环杂原子优选地选自N、O、S、和P以及N、S、和P的氧化形式,其条件是该环包含至少3个环原子。而杂环基优选地是指饱和的环系统,它也包括包含1-3个双键的环系统,其条件是该环是非芳香族的。杂环基的非限制性实例包括氮代内酯、噁唑啉、哌啶基、哌嗪基、吡咯烷基、四氢呋喃基、以及四氢吡喃基。这些缩合环可以包含或可以不包含含有非芳香族杂原子的环,其条件是附接点是杂环基。例如,并且没有限制,以下是杂环基基团:
术语“水解”是指将一个RH-O-CO-、RH-O-CS-、或RH-O-SO2-部分断裂为RH-OH,优选地通过跨该断裂的键添加水。水解是使用技术人员熟知的不同方法进行的,其非限制性实例包括酸性和碱性水解。
术语“氧代”是指C=O基团,并且是指用C=O基团取代2个偕氢原子。
术语“任选取代”是指取代的或未取代的基团。该基团可以被一个或多个取代基例如像1、2、3、4或5个取代基取代。优选地,这些取代基选自下组,该组由以下各项组成:氧代、卤素、-CN、NO2、-N2+、-CO2R100、-OR100、-SR100、-SOR100、-SO2R100、-NR101R102、-CONR101R102、-SO2NR101R102、C1-C6烷基、C1-C6烷氧基、-CR100=C(R100)2、-CCR100、C3-C10环烷基、C3-C10杂环基、C6-C12芳基和C2-C12杂芳基,其中每个R100独立地是氢或C1-C8烷基;C3-C12环烷基;C3-C10杂环基;C6-C12芳基;或C2-C12杂芳基;其中每个烷基、环烷基、杂环基、芳基、或杂芳基任选地被1-3个卤素、1-3个C1-C6烷基、1-3个C1-C6卤烷基或1-3个C1-C6烷氧基基团取代。优选地,这些取代基选自下组,该组由以下各项组成:氯、氟、-OCH3、甲基、乙基、异-丙基、环丙基、乙烯基、乙炔基、-CO2H、-CO2CH3、-OCF3、-CF3和-OCHF2。
R101和R102独立地是氢;C1-C8烷基(任选地被-CO2H或其酯取代)、C1-C6烷氧基、氧代、-CR103=C(R103)2、-CCR、C3-C10环烷基、C3-C10杂环基、C6-C12芳基、或C2-C12杂芳基,其中每个R103独立地是氢或C1-C8烷基;C3-C12环烷基;C3-C10杂环基;C6-C12芳基;或C2-C12杂芳基;其中每个环烷基、杂环基、芳基、或杂芳基任选地被1-3个烷基基团或1-3个卤素基团取代,或R101和R102与它们附接的氮原子一起形成5-7元杂环。
术语“药学上可接受的”是指对于体内,优选地人类给药,是安全且非毒性的。
术语“药学上可接受的盐”是指是药学上可接受的盐。
术语“盐”是指在酸和碱之间形成的离子化合物。当在此提供的化合物包含酸官能度时,此类盐包括但不限于碱金属、碱土金属、以及铵盐。如在此使用的,铵盐包括含有质子化的氮碱和烷基化氮碱的盐。适用于药学上可接受的盐的示例性和非限制性的阳离子包括Na、K、Rb、Cs、NH4、Ca、Ba、咪唑鎓、和基于天然发生的氨基酸的铵阳离子。当在此利用的化合物包含碱官能度时,此类盐包括但不限于有机酸的盐,例如羧酸和磺酸、以及矿物酸,例如卤化氢、硫酸、磷酸等等。适用于药学上可接受的盐的示例性和非限制性的阴离子包括草酸盐,马来酸盐,乙酸盐,丙酸盐,琥珀酸盐,酒石酸盐,氯化物,硫酸盐,硫酸氢盐(bisalfate),单-、二-、和三元磷酸盐,甲磺酸盐,甲苯磺酸盐等等。
如在此使用的术语“治疗(treat、treating或treatment)”包括缓解、消除或改善疾病或病症或其一个或多个症状,防止另外的症状,改善或防止症状的基础代谢病因,抑制疾病或病症(例如阻滞或压制该疾病或病症的发展,减轻该疾病或病症,引起该疾病或病症的退化,减轻由该疾病或病症引起的状况,或压制该疾病或病症的症状,并且旨在包括预防。这些术语还包括减轻这些疾病或病症,例如,引起临床症状的退化。这些术语进一步包括实现治疗益处和/或预防益处。通过治疗益处是指根除或改善正治疗的基础障碍。而且,治疗益处是伴随与该基础障碍关联的生理症状中的一个或多个的根除或改善而实现的,这样使得在个体中观察到改进,尽管该个体仍受该基础障碍的折磨。对于预防益处,这些组合物被给予具有发展具体的疾病的风险的个体,或给予到报告了疾病的生理学症状中一个或多个的个体,尽管对这种疾病还未进行诊断。
术语“防止(preventing或prevention)”是指获得疾病或障碍的风险的降低(即,在可能暴露于或易遭受该疾病但尚未经历或展示该疾病的症状的受试者体内引起该疾病的临床症状中的至少一个不发展)。这些术语进一步包括引起这些临床症状不在例如处于遭受此种疾病或障碍的风险的受试者中发展,从而基本上避免该疾病或障碍发作。
术语“有效量”是指有效于通过鼻内给予在此所述的化合物或组合物来治疗病症或障碍的量。在一些实施例中,在此所述的组合物或剂型中任一种的有效量是用于治疗由血红蛋白介导的障碍或如下的障碍的量,所述障碍受益于对其有需要的受试者的由在此所述的组合物或剂型中任一种进行的组织和/或细胞加氧。
如在此使用的术语“载体”是指促进将化合物掺入到细胞(例如红血细胞或组织)中的相对无毒的化学化合物或试剂。
如在此使用的,“前药”是化合物,在给予之后,该化合物代谢或以其他方式转化为相对于至少一个特性的一个活性形式或多个活性形式。为了生产前药,药物活性化合物可以被化学修饰以使得它具有更少活性或无活性,但是该化学修饰是使得通过代谢或其他生物过程产生活性形式的该化合物。相对于该药物,前药可以具有改变的代谢稳定性或转运特征、更少的副作用或更低的毒性。例如,参见参考文献努格雷迪(Nogrady),1985,医药化学:生物化学途径(Medicinal Chemistry A Biochemical Approach),牛津大学出版社,纽约,第388-392页。前药还可以使用不是药物的化合物来制备。
化合物
在本发明的某些方面,提供了具有化学式(I)的化合物:
或其互变异构体,或其各自药学上可接受的盐或其药学上可接受的盐,其中
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该-L1L2R3是α或β位取代的;
其中Z和-CV1V2H连接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R4是OH、卤素、C1-C6烷氧基、C3-C6环烷氧基或O-R,其中R是前药部分,其中该C1-C6烷氧基任选地被1-5个卤素取代;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
并且R3、B、和C是如下定义的。
在一个情况下,
R3是C1-C6烷基、C3-C8环烷基、C1-C6烷氧基、C3-C8环烷氧基、或-NR1R2;
每个R1和R2独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-10元杂环或5-10元杂芳基,该杂环或杂芳基各自包含高达5个环杂原子,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中每个烷基、环烷基、杂环、芳基或杂芳基被任选取代,或R1和R2与它们附接的氮原子一起形成任选取代的4-7元杂环;
环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;并且
环C是任选取代的C6-C10芳基或任选取代的包含1-3个氮原子或N的氧化形式的5-10元杂芳基;
在另一个情况下,
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;并且
R19是氢或前药部分R。
在某些实施例中,L1是键。
在某些实施例中,L2是C=O。在某些实施例中,L2是SO2。
在一个实施例中,环C是任选地被1-4个以下项取代的苯基:卤素、氧代、-OR2、C1-C6烷基和/或C1-C6烷氧基,
在本发明的某些方面,提供了具有化学式(II)的化合物:
或其互变异构体,或其各自药学上可接受的盐或其药学上可接受的盐,其中
R3是C1-C6烷基、C3-C8环烷基、C1-C6烷氧基、C3-C8环烷氧基、或-NR1R2;
每个R1和R2独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-10元杂环或5-10元杂芳基,该杂环或杂芳基各自包含高达5个环杂原子,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中每个烷基、环烷基、杂环、芳基或杂芳基被任选取代,或R1和R2与它们附接的氮原子一起形成任选取代的4-7元杂环;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该-LCOR3是α或β位取代的;
环C是任选取代的C6-C10芳基或任选取代的包含1-3个氮原子或N的氧化形式的5-10元杂芳基;
其中Z和-CV1V2H连接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R4是OH、卤素、C1-C6烷氧基、C3-C6环烷氧基或O-R,其中R是前药部分,其中该C1-C6烷氧基任选地被1-5个卤素取代;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
在某些实施例中,t是0。在某些实施例中,t是1。在某些实施例中,t是2。在某些实施例中,t是3。
如在此使用的,R60可以是氢,其条件是该COOR60不连接到氮原子。
优选地,在某些实施例中,Y和Z均不是杂原子或包含杂原子的部分。优选地,Y和Z中一项是亚甲基或取代的亚甲基,并且另一项是杂原子或包含杂原子的部分。更优选地,Y是亚烷基,并且Z是杂原子或包含杂原子的部分,其又更优选地是氧。
优选地,V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
在一些实施例中,V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O。
在本发明的某些方面,该具有化学式(II)的化合物具有化学式(III):
其中Y-Z是-CH2O-或-CH2CH2-,并且剩余的取代基是如在此所定义的。
在一些实施例中,R4和-CHO连接到环C上的相邻原子。
在本发明的某些方面,该具有化学式(II)的化合物具有化学式(IIIA):
其中环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基;
R5是氢、C1-C6烷基或前药部分R;
R6是卤素、C1-C6烷基、C3-C6环烷基、C1-C6烷氧基、C3-C6环烷氧基,其中该C1-C6烷基任选地被1-5个卤素取代;并且
p是0、1、2或3。
在一些实施例中,该化合物具有化学式IIIB、IIIC、或IIID:
其中
是如在此所定义的任选取代的4-10元杂环;
R5是氢、C1-C6烷基或前药部分;
R6是卤素、C1-C6烷基、C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素取代;并且
p是0、1、2或3。
在一些实施例中,环B被1-3个以下项取代:卤素、C1-C6烷基、COR15、或COOR15;并且
R15是C1-C6烷基、C3-C10环烷基、C6-C10芳基、包含高达5个环杂原子的5-10元杂芳基或4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代。
在本发明的某些方面,提供了具有化学式(IV)的化合物:
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该-L1L2R1是α或β位取代的;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
R19是氢或前药部分R;并且
其中Z和-CV1V2H附接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
在某些实施例中,Z是CH2、O、S、SO、SO2或NH。在某些实施例中,Z是O、S、SO或SO2。优选地,Z是O,并且其中剩余的变量是在此所定义的。
在某些实施例中,Y是CR10R11、O、S、SO、SO2、或NR10;其中每个R10和R11独立地是氢或C1-C3烷基。在某些实施例中,Y是CR10R11,其中每个R10和R11独立地是氢或C1-C3烷基。优选地,Y是CH2,并且其中剩余的变量是在此所定义的。
在某些实施例中,t是0。在某些实施例中,t是1。在某些实施例中,t是2。在某些实施例中,t是3。
优选地,CV1V2是C=V,其中V是O,并且其中剩余的变量是在此所定义的。
在某些实施例中,提供了具有化学式(V)的化合物:
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
Z是O、S、SO或SO2;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;并且
R19是氢或前药部分R。
在某些实施例中,提供了具有化学式(VI)的化合物:
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
R4是-OR19或C1-C6烷氧基;并且
R19是氢或前药部分R。
在一个实施例中,R4是-OH。
在某些实施例中,R3是任选取代的苯基。在其他实施例中,R3是任选取代的吡啶。在某些实施例中,R3是任选取代的吡唑。
在某些实施例中,R3是选自下组,该组由以下各项组成:
在某些实施例中,提供了具有化学式(IV)和(V)的化合物,其中
是
在一个实施例中,环B是包含选自N、S、或O的杂原子的5-6元杂环。在一个实施例中,环B是包含N作为杂原子的5-6元杂环。
在某些实施例中,环B是选自下组,该组由以下各项组成:
在某些实施例中,L1是键。
在某些实施例中,L2是C=O。在某些实施例中,L2是SO2。
在一个实施例中,环C是任选地被1-4个以下项取代的苯基:卤素、氧代、-OR2、C1-C6烷基和/或C1-C6烷氧基,
在一些实施例中,该化合物选自下组,该组由以下各项组成
或其N氧化物,其中
每个P和Q独立地是选自CHR17、NCOR15、NCO2R15;N-O、O、S、SO、以及SO2;
每个R1和R2独立地是氢、C1-C6烷基、C6-C10芳基、5-10元杂芳基或包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基任选地被取代,R1和R2一起可形成3-7元环,优选地具有1-2个杂原子的4-7元环;
R15是C1-C6烷基、C6-C10芳基、包含高达5个环杂原子的5-10元杂芳基或4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代;
R17是C1-C6烷基、C6-C10芳基、包含高达5个环杂原子的5-10元杂芳基或4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代;
并且r是0、1、或2。
在本发明的某些实施例中,提供了具有以下化学式的化合物:
在本发明的某些实施例中,提供了具有以下化学式的化合物:
或其N氧化物,或其各自药学上可接受的盐。
在此提供的化合物包括在实例部分中的那些。
前药部分
在一个方面,R是氢、包含磷酸盐或磷酸氢盐的部分、或另一个前体部分或前药部分。优选地,该前药部分为该活性部分(其中R是氢)赋予至少2倍、更优选4倍增强的溶解度和/或生物利用率,并且更优选在体内水解。这些前体部分在结构和功能上是在此所定义的。
在一个实施例中,R是-COR90、CO2R91、或CONR92R93,其中
R90和R91独立地是C1-C6烷基、C3-C8环烷基、4-9元杂环、或5-10元杂芳基,每个包含至少1个碱性氮部分;并且
R92和R93独立地是C1-C6烷基;C3-C8环烷基、4-9元杂环、或5-10元杂芳基,每个包含至少1个碱性氮部分;或R92和R93与它们连接的氮原子一起形成被至少1个氨基、C1-C6烷基氨基、或二C1-C6烷基氨基基团取代的4-9元杂环。
在某些实施例中,R是-C(O)R31、C(O)OR31、或CON(R13)2,
每个R31独立地是C1-C6烷基;C3-C8环烷基、4-9元杂环、或5-10元杂芳基,包含至少1个碱性氮部分;并且
每个R13独立地是C1-C6烷基;C3-C8环烷基、4-9元杂环、或5-10元杂芳基,包含至少1个碱性氮部分;或2个R13与它们连接的氮原子一起形成被至少1个氨基、C1-C6烷基氨基、或二C1-C6烷基氨基基团取代的4-9元杂环。
在一个方面,R是C(O)OR31、C(S)OR31、C(O)SR31或COR31,其中R31是如在此处所定义的。
在一个实施例中,R31是具有化学式(CR32R33)eNR34R35的基团,其中
每个R32和R33独立地是H、C1-C8烷基、C3-C9杂环基、C3-C8环烷基、C6-C10芳基、C3-C9杂芳基,或R32和R33与它们连接的碳原子一起形成C3-C8环烷基、C6-C10芳基、C3-C9杂环基或C3-C9杂芳基环系统,或2个邻近的R32部分或2个邻近的R33部分与它们连接的碳原子一起形成C3-C8环烷基、C6-C10芳基、C3-C9杂环基或C3-C9杂芳基环系统;
每个R34和R35是C1-C8烷基、C3-C9杂环基、C3-C8环烷基、或R34和R35与它们连接的氮原子一起形成C3-C8环烷基或C3-C9杂环基环系统;
每个杂环和杂芳基环系统任选地被C1-C3烷基、-OH、氨基和羧基基团取代;并且
e是自1至4的整数。
在一些较不优选的实施例中,R34和R35可以是氢。
在一个实施例中,下标e优选是2,并且优选地每个R32和R33独立地选自下组基团,该组由以下各项组成:H、CH3、以及如下的成员,其中R32和R33结合在一起形成环丙基、环丁基、环戊基、环己基、或1,1-二氧代-六氢-lΔ6-噻喃-4-基或四氢吡喃-4-基基团。
关于前药基团,优选的实施例是如下化合物,其中NR34R35是吗啉代。
在一个实施例中,R是:
其中
每个R32和R33独立地是H、C1-C8烷基,或任选地,如果都存在于相同的取代基上,可以结合在一起形成C3-C8环烷基、C6-C10芳基、C3-C9杂环基或C3-C9杂芳基环系统。
在此实施例中,每个R32和R33独立地是H、CH3,或结合在一起形成环丙基、环丁基、环戊基、环己基、1,1-二氧代-六氢-lλ6-噻喃-4-基或四氢吡喃-4-基基团。
在一个优选实施例中,该前药部分连接到该活性分子的剩余部分是足够稳定的,使得该前药的血清半衰期是从约8至约24小时。
在本发明的一个实施例中,该前药部分包括具有靠近7.5的生理pH的pKa的叔胺。对于此目的,具有在7.5的1个单位内的pKa的任何胺是适合的替代方案。该胺可以通过吗啉代基团的胺提供。6.5至8.5的此pKa范围允许显著浓度的该碱性中性胺存在于轻度碱性小肠中。碱性中性形式的该胺前药是亲脂性的并且是通过该小肠的壁吸收到血液中。在吸收到血流中后,该前药部分被天然存在于血清中的酯酶切割以释放活性化合物。
R的实例包括但不限于:
在另一个实施例中,R是如以下制表的:
其N氧化物,或其各自药学上可接受的盐。
在另一个方面,R是,
其中
R36是低级烷基(例如C1-C6烷基)。
在又另一个方面,R是:
其中X1、Y1和X2是如在此所定义的。
在一个实施例中,X1选自下组,该组由以下各项组成:O、S和NR37,其中R37是氢或C1-C6烷基;
Y1是-C(R38)2或糖部分,其中每个R38独立地是氢或C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基;
X2选自下组,该组由以下各项组成:卤素、C1-C6烷氧基、二酰基甘油、氨基、C1-C6烷基氨基、C1-C6二烷基氨基、C1-C6烷硫基、PEG部分、胆汁酸部分、糖部分、氨基酸部分、二肽或三肽、PEG羧酸、以及-U-V,其中
U是O或S;并且
V选自下组,该组由以下各项组成:C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、C3-C9杂芳基、C(W2)X3、PO(X3)2、以及SO2X3;
其中W2是O或NR39
其中R39是氢或C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基;并且
每个X3独立地是氨基、羟基、巯基、C1-C6烷基、杂烷基、环烷基、杂环基、芳基、或杂芳基、C1-C6烷氧基、C1-C6烷基氨基、C1-C6二烷基氨基、C1-C6烷硫基、基于胆汁酸的烷氧基基团、糖部分、PEG部分、以及-O-CH2-CH(OR40)CH2X4R40,
其中:
X4是选自下组,该组由以下各项组成:O、S、S=O、以及SO2;并且
每个R40独立地是C10-C22烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基、C1-C8亚烷基、或C1-C8杂亚烷基。
每个杂环和杂芳基环系统任选地被C1-C3烷基、-OH、氨基和羧基基团取代。
在一个实施例中,本发明利用以下Y1基团:CH2、CHMe、CH(异丙基)、CH(叔丁基)、C(Me)2、C(Et)2、C(异丙基)2、以及C(丙基)2。
在另一个实施例中,本发明利用以下X2基团:
-OMe、-OEt、-O-异丙基、O-异丁基、O-叔丁基、-O-COMe、-O-C(=O)(异丙基)、-O-C(=O)(异丁基)、-O-C(=O)(叔丁基)、-O-C(=O)-NMe2、-O-C(=O)-NHMe、-O-C(=O)-NH2、-O-C(=O)-N(H)-CH(R41)-CO2Et,其中R41是选自存在于必需氨基酸中的侧链基团的侧链C1-C6烷基、或C3-C9杂环基基团;-O-P(=O)(OMe)2、-O-P(=O)(O-异丙基)2、以及-O-P(=O)(O-异丁基)2。每个杂环任选地被一个或多个(优选1-3个)C1-C3烷基、-OH、氨基和/或羧基基团取代。
在另一个实施例中,在一个实施例中,R是:
其中
X3独立地是C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基;并且
R42独立地是氢或C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基。
每个杂环任选地被一个或多个(优选1-3个)C1-C3烷基、-OH、氨基和/或羧基基团取代。
在一个实施例中,R是:
其中
每个X3独立地是氨基、羟基、巯基、C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基、C1-C6烷氧基、C1-C6烷基氨基、C1-C6二烷基氨基、C1-C6烷硫基、基于胆汁酸的烷氧基基团、糖部分、PEG部分、以及-O-CH2-CH(OR40)CH2X4R40,
其中:
X4是选自下组,该组由以下各项组成:O、S、S=O、以及SO2;并且
每个R40独立地是C10-C22烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、C3-C9杂芳基、C1-C8亚烷基、或C1-C8杂亚烷基;并且
R42独立地是氢或C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基。
在一些实施例中,R42独立地是氢或C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基;并且每个X3独立地是C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基、C1-C6烷氧基、C1-C6烷基氨基、C1-C6二烷基氨基、或C1-C6烷硫基。
在一些实施例中,R是由以下结构表示:
其中在以上实例中,R43是C10-C22烷基或亚烷基,R44是H或C1-C6烷基,并且R45表示存在于天然发生的α氨基酸中的侧链烷基基团;
其中R46是(CH2)n,n=2-4,R47是(CH2)n,n=1-3,并且R49是O或NMe。
在一个实施例中,R是:
在一个方面,R是-C(R200R201)O(R202R203)P(O)OR204NR205R206,其中每个R200、R201、R202、R203、R204 R205和R206独立地是H、C1-C8烷基、C3-C9杂环基、C3-C8环烷基、C6-C10芳基、C3-C9杂芳基,其中每个烷基、杂环基、环烷基、芳基、以及杂芳基是任选取代的。
在一些实施例中,R是-CH(R201)OCH2P(O)OR204NHR206,其中R201是C1-C8烷基,R204是任选取代的苯基。在一个实施例中,R206是-CHR207C(O)OR208,其中R207选自下组,该组由以下各项组成:这些天然发生的氨基酸侧链和其-CO2H酯,并且R208是C1-C8烷基。在一个实施例中,R206是任选地被1-3个CO2H、SH、NH2取代的C1-C6烷基,C6-C10芳基,以及C2-C10杂芳基。
在一个实施例中,R是:
在一个实施例中,R是:
其中Y1是-C(R38)2,其中每个R38独立地是氢或C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基。
可以用于或适合于制造本发明的化合物的不同聚乙二醇(PEG)部分和与其相关的合成方法描述于美国专利号6,608,076;6,395,266;6,194,580;6,153,655;6,127,355;6,111,107;5,965,566;5,880,131;5,840,900;6,011,042和5,681,567。
在一个实施例中,R是
其中
R50是-OH或氢;
R51是-OH、或氢;
W是-CH(CH3)W1;
其中W1是取代的C1-C8烷基基团,其包含在生理pH值任选带负电荷的部分,
所述部分选自下组,该组由以下各项组成:CO2H、SO3H、SO2H、-P(O)(OR52)(OH)、-OP(O)(OR52)(OH)、以及OSO3H,
其中R52是C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基。
每个杂环和杂芳基环系统任选地被一个或多个(优选1-3个)C1-C3烷基、-OH、氨基和/或羧基基团取代。
在一个实施例中,R是:
其中R53是H或C1-C6烷基。
在另一个方面,R是SO3H。
在另一个方面,R包括一个可切割的接头,其中术语“可切割的接头”是指在体内具有短半衰期的接头。在化合物中接头Z的断裂释放或产生该活性化合物。在一个实施例中,该可切割的连接物具有小于十小时的半衰期。在一个实施例中,该可切割的连接物具有小于一小时的半衰期。在一个实施例中,该可切割的接头的半衰期是在一分钟和十五分钟之间。在一个实施例中,该可切割的接头与以下结构具有至少一处连接:C*-C(=X*)X*-C*,其中C*是取代的或未取代的亚甲基基团,并且X*是S或O。在一个实施例中,该可切割的接头具有至少一处C*-C(=O)O-C*连接。在一个实施例中,该可切割的接头具有至少一处C*-C(=O)S-C*连接。在一个实施例中,该可切割的接头具有至少一处-C(=O)N*-C*-SO2-N*-连接,其中N*是-NH-或C1-C6烷基氨基。在一个实施例中,该可切割的接头被酯酶水解。
在一个实施例中,该接头是自我毁灭式接头,例如披露于美国专利公开2002/0147138,费尔斯通(Firestone);PCT申请号US 05/08161和PCT公开号2004/087075。在另一个实施例中,该接头是酶的底物。总体上参见鲁斯博姆(Rooseboom)等人,2004,药理学评论(Pharmacol.Rev.)56:53-102。
药物组合物
在本发明的另外的方面,提供了包括在此所述的任何化合物以及至少一种药学上可接受的赋形剂的组合物。
在另一个方面,本发明提供组合物,该组合物包括在此所述的任何化合物、以及药学上可接受的赋形剂。
此类组合物可以被配制用于不同的给予途径。尽管可能最经常使用适合用于口服递送的组合物,但是可以使用的其他途径包括经皮、静脉内、动脉内、肺部、直肠、经鼻、经阴道、经舌、肌内、腹膜内、皮内、颅内、以及皮下途径。用于给予在此所述的任何化合物的适合的剂型包括片剂、胶囊剂、丸剂、粉剂、气溶胶、栓剂、不经肠道的剂型、和口腔液体,包括悬浮液、溶液和乳剂。还可以使用持续释放剂型,例如以经皮贴剂形式。可以使用是本领域中的标准的方法来制备所有剂型(参见,例如,雷明顿制药科学(Remington’sPharmaceutical Sciences),第16版,A.奥斯陆(Oslo)编辑,伊斯顿Pa.1980)。
药学上可接受的赋形剂是非毒性的,帮助给药,并且不会不利地影响本发明的化合物的治疗益处。此类赋形剂可以是任何固体、液体、半固体或在气溶胶组合物的情况下是本领域的普通技术人员通常可用的气体赋形剂。依照本发明的药物组合物是通过常规手段使用本领域中已知的方法制备的。
在此披露的组合物可以与在药物制剂中常采用的任何媒介物和赋形剂结合使用,例如,滑石、阿拉伯胶、乳糖、淀粉、硬脂酸镁、可可油、水性或非水性溶剂、油、石蜡衍生物、乙二醇等。还可以将着色以及调味剂添加至制剂,具体地用于口服给药的那些。溶液可以使用水或生理学上可兼容的有机溶剂如乙醇、1,2-丙二醇、聚乙二醇、二甲亚砜、脂肪醇、甘油三酯、甘油的偏酯等等制备。
固体药物赋形剂包括淀粉、纤维素、羟丙基纤维素、滑石、葡萄糖、乳糖、蔗糖、明胶、麦芽、水稻、面粉、白垩、硅胶、硬脂酸镁、硬脂酸钠、单硬脂酸甘油酯、氯化钠、干燥脱脂牛奶等等。液体和半固体赋形剂可以选自甘油、丙二醇、水、乙醇以及各种油,包括石油、动物、植物或合成来源的那些,例如,花生油、大豆油、矿物油、芝麻油等。在某些实施例中,在此提供的组合物包括α-生育酚、阿拉伯胶、和/或羟丙基纤维素中的一种或多种。
在一个实施例中,本发明提供了持续释放配制品,如包括有效量的在此提供的化合物的长效药物(drug depot)或贴剂。在另一个实施例中,该贴剂进一步包括在α-生育酚的存在下单独地或以组合形式存在的阿拉伯树胶或羟丙基纤维素。优选地,该羟丙基纤维素具有从10,000至100,000的平均MW。在一个更优选实施例中,该羟丙基纤维素具有从5,000至50,000的平均MW。
本发明的化合物和药物组合物可以单独使用或与其他化合物组合使用。当伴随另一种试剂给予时,可以以如下任何方式进行共给予,其中两者的药理学效应同时在该患者体内表现出来。因此,共给予不要求使用单一药物组合物、相同的剂型、或甚至相同的给予途径用于给予本发明的化合物和其他试剂两者,或不要求在正好相同的时间给予这些两种试剂。然而,最便利地是通过相同的剂型和相同的给予途径在基本上相同的时间完成共给予。显而易见地,依照本发明,此类给予最有利地是通过在新的药物组合物中同时递送两种活性成分。
治疗方法
在本发明的方面,提供了用于增加组织和/或细胞加氧的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物或组合物。
在本发明的方面,提供了用于增加受试者体内的血红蛋白S的氧亲和力的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物或组合物。
在本发明的方面,提供了用于治疗与氧缺乏相关联的病况的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物或组合物。
在本发明的另外的方面,提供了用于治疗与镰状细胞性贫血相关的缺氧的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物或组合物。
在本发明的另外的方面,提供了用于治疗镰状细胞疾病的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物中的化合物或组合物。在本发明的仍另外的方面,提供了用于治疗癌症、肺部障碍、中风、高原病、溃疡、压疮、阿尔茨海默病、急性呼吸系统疾病综合征、以及创伤的方法,该方法包括向对其有需要的受试者给予治疗有效量的在此所述的任何化合物中的化合物或组合物。
合成方法
还提供了用于制造在此所述的化合物的某些方法。这些反应优选地是在适合的惰性溶剂(在阅读本披露时技术人员会清楚的)中进行的,持续足够的时间段以确保实质性地完成该反应,如通过薄层层析法,1H-NMR等观察到的。如果需要加速该反应,可将该反应混合物加热,如技术人员熟知的。如果必要,通过本领域已知的各种方法(如结晶、沉淀、柱层析法等等)纯化最终和中间化合物,如在阅读本披露时技术人员会清楚的。
用于合成具有化学式(I)的化合物的示意性和非限制性方法是以下示意性地显示的。
L、R3和R70是如在此处所述的;
A5和B5独立地是NR14、O、S、S(O)x、NBoC、CH2、CHR14、C(R14)2,其条件是当A5和B5两者存在于环中时,两者都不是CH2、CHR14、C(R14)2,并且其条件是如果仅单一的A5或B5存在于环中,则该A5或B5不是CH2、CHR14、C(R14)2;
R14是C1-C6烷基、COR15或COOR15;其中R15是任选取代的C1-C6烷基、任选取代的C6-C10芳基、任选取代的包含高达5个环杂原子的5-10元杂芳基、或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式;
X和X5各自表示离去基团并且独立地是选自Cl、Br、和I。
X6表示CR、N、O、S(O)x;其中x是0、1、或2;
Y5表示选自Cl、F、Br、I、OSO2R71和OSO2Ar的离去基团;
R71是C1-C6烷基;
Ar是任选地被1-3个卤素和/或C1-C4烷基基团取代的苯基;
n是0、1、或2。
当在上文的结构中使用的变量被用在这些方案中时,该背景使得清楚该变量指的是什么。
通用合成方案
用于从取代的亚甲基醇(1)和羟基(杂)芳基醛衍生物(3a/3b)制备芳氧基/杂芳基醚类似物(4a/4b)的通用方法A。在氮下,将羟基(杂)芳基醛衍生物(3a/3b)(0.1-2mmol)与取代的亚甲基醇(1)(0.8至1.2当量)以及PPh3(1-1.5当量)在无水THF(1-10mL)中的混合物进行搅拌直到完全溶解。将该溶液在冰浴上冷却至0℃,并且经1-20min时间逐滴添加在THF或甲苯中的DIAD或DEAD(1.1当量)。允许该冰冷却浴经90min终止,并且将该混合物在室温搅拌2-48小时。将该混合物搅拌10min,然后通过二氧化硅垫过滤。将该二氧化硅用乙酸乙酯2-20mL洗涤。将合并的滤液蒸发并且将残余物在高真空(highvac)上干燥。将残余物通过制备型HPLC或快速硅胶层析法纯化。
用于从取代的亚甲基卤化物(2)和羟基(杂)芳基醛衍生物(3a/3b)制备芳氧基/杂芳基醚类似物(4a/4b)的通用方法B。在氮气氛下,将羟基(杂)芳基醛衍生物(3a/3b)(0.1-2mmol、1-4当量)、取代的亚甲基氯化物或溴化物(2)(1当量)、以及K2CO3(2-5当量)在DMF或乙腈(1至10mL)中的混合物(还可以添加催化量的NaI或Bu4NI)在室温搅拌或加热直到120℃持续0.5-8h。在工作进程A中,将水添加到该反应混合物中,收集沉淀的产物,用水洗涤,并且然后经受备型HPLC或快速硅胶层析法纯化。在工作进程B(对于未沉淀的产物)中,在0℃添加稀释的HCl或水性NH4Cl以将pH调节至~7,将该反应混合物在乙酸乙酯或二氯甲烷和水性氯化钠之间进行分配,并且将有机层分离,干燥,并在真空下去除溶剂,以提供粗产物,将该粗产物通过自动化硅胶柱层析法使用适当的溶剂混合物(例如,乙酸乙酯/己烷)进行纯化。
用于制备取代的亚甲基氯化物(2a)的通用方法C。在0℃或室温,向取代的亚甲基醇(1)(0.1至2mmol)在DCM(1-10mL)中的溶液中逐滴添加SOCl2(2当量至5当量)。将该反应混合物在室温搅拌10min至6h,或直至判定反应完成(LC/MS)。在旋转蒸发器上,将该反应混合物浓缩至干燥。将粗氯化物残余物悬浮于甲苯中,进行超声处理并且浓缩至干燥。将该过程重复三次并且在真空下干燥以给出取代的亚甲基氯化物(2),通常呈灰白色固体,将其用于下一步骤而不进行进一步纯化。可替代地,然后添加水性1N Na2CO3溶液以产生pH~8的溶液。将该混合物用DCM(3x 10-50mL)萃取,用硫酸钠进行干燥,并且浓缩至粗的取代的亚甲基氯化物(2a),然后将其通过硅胶柱层析法(0-100%乙酸乙酯-己烷)纯化。
用于制备取代的亚甲基溴化物(2b)的通用方法D。在0℃或室温,向取代的亚甲基醇(1)(0.1至2mmol)在DCM(1-10mL)中的溶液中逐滴添加Ph3P Br2(2当量至5当量)。将该反应混合物在室温搅拌10min至2h,或直至判定反应完成(LC/MS)。在旋转蒸发器上,将该反应混合物浓缩至干燥。将残余物通过硅胶柱层析法(0-100%乙酸乙酯-己烷)纯化以提供纯溴化物2b。
用于制备杂环亚甲基衍生物9、10、12和13的通用方法E。通过LAH或DIBAL进行的杂环己烯甲酸酯8的酯基团的还原给出相应的醇9-OH(步骤4)。醇9-OH与亚硫酰氯、Ph3PBr2(或CBr4-Ph3P或PBr3)、或烷基/芳基磺酰氯的另外的反应产生对应的10-X氯化物、溴化物或磺酸酯(步骤5)。
可替代地,在钯催化的氢化作用条件下,杂环己烯甲酸酯8的双键被还原以给出顺式-杂环己烷11-顺式甲酸酯(步骤6)。通过LAH或DIBAL进行的11-顺式的酯基团的还原产生顺式-醇12-OH-顺式(步骤8)。醇12-OH-顺式向其氯化物、溴化物或磺酸酯(例如甲磺酸酯、甲苯磺酸酯)13-X-顺式的转化可以通过使用亚硫酰氯、或Ph3PBr2、或磺酰氯(例如甲磺酰氯或对甲苯磺酰氯)实现(步骤9)。这些顺式-环己烷甲酸酯11-顺式还可以通过用醇性醇盐(例如,乙醇盐)溶液处理被异构为热力学上更稳定的反式-异构体11-反式。类似地,11-反式酯至12-反式醇和13-X-反式卤化物的转化是通过实施步骤8和步骤9的类似于针对相应的顺式异构体的这些的条件实现的。
通过通用方法A或B进行的(杂)环亚甲基衍生物9、10、12和13与羟基(杂)芳基醛衍生物(3a/3b)的偶联提供相应的芳氧基/杂芳基醚类似物(4c和4d)。
用于制备杂环亚甲基衍生物18、19、20和21的通用方法F。通过在有机碱(例如胡宁氏碱存在下(步骤1)用三氟甲磺酸化剂(例如,三氟甲磺酸酐)进行处理,酮酯14被转化为三氟甲磺酸酯中间体15。三氟甲磺酸酯15与硼酸或酯的铃木(Suzuki)偶联提供杂环甲酸酯16(步骤2)。通过LAH或DIBAL进行的酯基团的后续还原给出相应的醇18(步骤3)。醇18与亚硫酰氯、Ph3PBr2(或CBr4-Ph3P或PBr3)、或烷基/芳基磺酰氯的另外的反应产生对应的19氯化物、溴化物或磺酸酯(步骤4)。
可替代地,在钯催化的氢化作用条件下,16的双键被还原以给出饱和杂环类似物17(步骤5)。通过LAH或DIBAL进行的17的酯基团的还原产生醇20(步骤7)。醇20向其氯化物、溴化物或磺酸酯(例如甲磺酸酯、甲苯磺酸酯)21的转化可以通过与亚硫酰氯、或Ph3PBr2、或磺酰氯(例如甲磺酰氯或对甲苯磺酰氯)反应而实现(步骤8)。
通过通用方法A或B进行的(杂)环亚甲基衍生物18、19、20和21与羟基(杂)芳基醛衍生物(3a/3b)的偶联提供相应的芳氧基/杂芳氧基醚类似物(4e和4f)。
根据在此所述的反应序列制备手性吡咯烷亚甲基衍生物25和26。吡咯烷酯24是经由烯烃22与自蚁醛和氨基酸23烯烃(步骤1)原位产生的甲亚胺-叶立德(ylide)的1,3-偶极环加成产生的。酯向醇24的后续还原以及进一步转化25是通过此处所述的类似方法完成的。如果使用一个手性助剂基团(例如手性噁唑烷酮衍生物22a),还可以获得旋光活性的吡咯烷衍生物25和26。通过通用方法A或B进行的25和26与羟基(杂)芳基醛衍生物(3a/3b)的偶联提供相应的芳氧基/杂芳氧基醚类似物(4)。
与此处所述的四氢噻吩(即,20和21,A=S)的通用合成分开,还描述了向着这个类别的类似物的一个不同合成途径。
具有C-N键的其他杂环类似物(化合物5)是通过施用布赫瓦尔德(Buchwald)/哈特维希(Hartwig)氨化条件来合成的。环状胺(1)中许多是可商购的(例如,1a、1b、1c、1d、以及1e)。
根据本领域的普通技术人员已知的方法,具有化学式-CONHR95和-CONHOR95的受保护的酰胺可以被转化,例如,水解为对应的酰胺。
方案1
可以通过通用合成方案1合成具有结构4的化合物。羧酸衍生物1的还原给出羟基甲基类似物2,其可以经由铜-介导的N-芳基化反应(CuI、Ar-I、碱(例如N,N-二甲基乙二胺以及磷酸钾,热)被N-衍生化,以给出关键的羟基甲基中间体3。3与苯酚醛4的偶联经由典型光延(Mistunobu)条件使用三苯基膦或聚合物负载三苯基膦产生所希望的醛类似物5。A1是如在此定义的杂原子或烃基部分。
通用方法步骤1-将羧酸衍生物1还原为甲基醇2:在0℃向羧酸1(1-10mmol)在MeOH或EtOH(2-10mL)中的悬浮液中添加SOCl2(1.5当量)。在室温下搅拌1-12h之后,将它进行浓缩,以去除所有溶剂,在高真空下干燥以给出相应的甲酯或乙酯。将该酯溶解于MeOH或EtOH(5-30mL),在0℃向这一溶液中添加NaBH4(1-4当量),将该混合物加温至室温并搅拌另外1-24h。将该混合物用饱和NH4Cl淬灭,过滤掉不溶物,并且将滤液进行浓缩,以给出粗产物,将其通过快速硅胶柱层析法纯化以给出相应的羟基亚甲基化合物2。
通用方法步骤2-N-烷基化(1a至1b):羧酸酯1a(R1=H)可首先被烷基化并且然后还原以给出N-烷基羟基亚甲基类似物1b(R1=烷基)。在一个典型程序中,羧酸酯1a(1-10mmol)首先被溶解于DMF(2-20mL)中;然后向其中添加碱,例如NaH或Cs2CO3(1-1.2当量),随后添加卤代烷(例如BnBr)(0.9-1.5当量)。允许该反应在室温下进行,在40℃至115℃加热持续0.5至24h。在工作进程A中,将水添加到该反应混合物中,收集沉淀的产物,用水洗涤,并且然后经受备型HPLC或快速硅胶层析法纯化。在工作进程B(对于未沉淀的产物)中,在0℃添加稀释的HCl或水性NH4Cl以将pH调节至~7,将该反应混合物在乙酸乙酯或二氯甲烷和水性氯化钠之间进行分配,并且将有机层分离,干燥,并在真空下去除溶剂,以提供粗产物,将该粗产物通过自动化硅胶柱层析法,反应适当的溶剂混合物(例如,乙酸乙酯/己烷)进行纯化。
通用方法步骤3-自2a至2c的铜-介导的N-芳基化:对于环胺(X=H,H),向羟基亚甲基化合物2a(1-10mmol)和(杂)芳基碘化物(1-1.5当量)在iPrOH(0.5-10mL)中的溶液中添加乙烯二醇(1.3当量)以及CuI(6.7mol%),随后K3PO4(1.3当量),然后将其脱气并且在88℃加热持续6-24h。
可替代地,对于内酰胺(X=O),向羟基亚甲基化合物2a(1-10mmol)和(杂)芳基碘化物(1-1.5当量)在二噁烷(2-20mL)中的溶液中添加CuI(0.17当量)、N,N-二甲基乙二胺(0.17当量)、K3PO4(1.7当量),然后将其脱气并且在100℃加热持续6-48h。
针对两个程序的工作进程:将该反应混合物冷却至室温,将该混合物用EtOAc和水进行稀释,分离有机层,并且将水层用EtOAc进行萃取,将有机层合并,用盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过快速硅胶柱析法纯化以给出N-芳基/杂芳基化合物2c。
通用方法C-光延条件在氮下,将羟基(杂)芳基醛衍生物(4)(0.1-2mmol)与取代的亚甲基醇(3)(0.8至1.2当量)以及(聚合物负载的)PPh3(1-1.5当量)在无水THF(1-10mL)中的混合物进行搅拌直到完全溶解。将该溶液在冰浴上冷却至0℃,并且经1-20min时间逐滴添加在THF或甲苯中的DIAD或DEAD(1.1当量)。允许该冰冷却浴经90min终止,并且将该混合物在室温搅拌2-48小时。将该混合物通过二氧化硅垫过滤。将该二氧化硅用乙酸乙酯2-20mL洗涤。将合并的滤液蒸发并且将残余物在高真空(highvac)上干燥。将残余物通过制备型HPLC或快速硅胶层析法纯化。
可以通过通用合成方案1合成具有结构5的化合物。羧酸衍生物1的还原给出羟基甲基类似物2,其可以经由铜-介导的N-芳基化反应(CuI、Ar-I、碱(例如N,N-二甲基乙二胺以及磷酸钾,热)被单一的烷基卤化物(碱,R1X,热)或芳基卤化物(ArX)N-烷基化,以给出关键的羟基甲基中间体3。3与苯酚醛4的偶联经由典型光延(Mistunobu)条件使用三苯基膦或聚合物负载三苯基膦产生所希望的醛类似物5。A1是如在此定义的杂原子或烃基部分。
通用方法步骤1-将羧酸衍生物1还原为甲基醇2:在0℃向羧酸1(1-10mmol)在MeOH或EtOH(2-10mL)中的悬浮液中添加SOCl2(1.5当量)。在室温下搅拌1-12h之后,将它进行浓缩,以去除所有溶剂,在高真空下干燥以给出相应的甲酯或乙酯。将该酯溶解于MeOH或EtOH(5-30mL),在0℃向这一溶液中添加NaBH4(1-4当量),将该混合物加温至室温并搅拌另外1-24h。将该混合物用饱和NH4Cl淬灭,过滤掉不溶物,并且将滤液进行浓缩,以给出粗产物,将其通过快速硅胶柱层析法纯化以给出相应的羟基亚甲基化合物2。
通用方法步骤2-铜-介导的N-芳基化:对于环胺(X=H,H),向羟基亚甲基化合物2(1-10mmol)和(杂)芳基碘化物(1-1.5当量)在iPrOH(0.5-10mL)中的溶液中添加乙烯二醇(1.3当量)以及CuI(6.7mol%),随后K3PO4(1.3当量),然后将其脱气并且在88℃加热持续6-24h。可替代地,对于内酰胺(X=O),向羟基亚甲基化合物2(1-10mmol)和(杂)芳基碘化物(1-1.5当量)在二噁烷(2-20mL)中的溶液中添加CuI(0.17当量)、N,N-二甲基乙二胺(0.17当量)、K3PO4(1.7当量),然后将其脱气并且在100℃加热持续6-48h。
针对两个程序的工作进程:将该反应混合物冷却至室温,将该混合物用EtOAc和水进行稀释,分离有机层,并且将水层用EtOAc进行萃取,将有机层合并,用盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过快速硅胶柱析法纯化以给出N-芳基/杂芳基化合物3。
通用方法步骤2b-N-烷基化:羧酸酯1可首先被烷基化并且然后还原以给出N-烷基羟基亚甲基类似物3。在一个典型程序中,羧酸酯1(1-10mmol)首先被溶解于DMF(2-20mL)中;然后向其中添加碱,例如NaH或Cs2CO3(1-1.2当量),随后添加卤代烷(例如BnBr)(0.9-1.5当量)。允许该反应在室温下进行,在40℃至115℃加热持续0.5至24h。在工作进程A中,将水添加到该反应混合物中,收集沉淀的产物,用水洗涤,并且然后经受备型HPLC或快速硅胶层析法纯化。在工作进程B(对于未沉淀的产物)中,在0℃添加稀释的HCl或水性NH4Cl以将pH调节至~7,将该反应混合物在乙酸乙酯或二氯甲烷和水性氯化钠之间进行分配,并且将有机层分离,干燥,并在真空下去除溶剂,以提供粗产物,将该粗产物通过自动化硅胶柱层析法,反应适当的溶剂混合物(例如,乙酸乙酯/己烷)进行纯化。
通用方法C-光延条件在氮下,将羟基(杂)芳基醛衍生物(4)(0.1-2mmol)与取代的亚甲基醇(3)(0.8至1.2当量)以及(聚合物负载的)PPh3(1-1.5当量)在无水THF(1-10mL)中的混合物进行搅拌直到完全溶解。将该溶液在冰浴上冷却至0℃,并且经1-20min时间逐滴添加在THF或甲苯中的DIAD或DEAD(1.1当量)。允许该冰冷却浴经90min终止,并且将该混合物在室温搅拌2-48小时。将该混合物通过二氧化硅垫过滤。将该二氧化硅用乙酸乙酯2-20mL洗涤。将合并的滤液蒸发并且将残余物在高真空(highvac)上干燥。将残余物通过制备型HPLC或快速硅胶层析法纯化。
前药合成
这些酯前药的合成以带有叔胺的游离羧酸起始。对于酯形成,在非质子溶剂中,该自由酸被激活并且然后在惰性碱(例如三乙胺)的存在下与游离醇基团反应,以提供该酯前药。该羧酸的激活条件包括在非质子溶剂中使用草酰氯或亚硫酰氯(任选地与催化量的二甲基甲酰胺)形成该酰基氯,随后蒸发。非质子溶剂的实例包括但不限于亚甲基氯化物、四氢呋喃等等。可替代地,激活可以通过使用试剂如BOP(苯并三唑-l-基氧基三(二甲氨基)六氟磷酸鏻等等在原位进行(参见纳吉(Nagy)等人,1993,美国国家科学院院刊(Proc.Natl.Acad.Sci.USA)90:6373-6376),随后与该游离醇反应。这些酯产物的分离可能通过以下项实现:用有机溶剂(如乙酸乙酯或亚甲基氯化物)针对轻度酸性水性溶液进行提取;随后对该酸性水相进行碱处理以使得它是碱性的;随后用有机溶剂如乙酸乙酯或亚甲基氯提取;蒸发该有机溶剂层;并且自溶剂如乙醇重结晶。任选地,该溶剂可被酸(例如HCl)或乙酸酸化提供其药学上可接受的盐。作为替代方案,该粗反应可以通过带有处于质子化形式的磺酸基团的离子交换柱,用去离子水洗涤,并用氨水洗脱;随后蒸发。
带有叔胺的适合的游离酸是可商购的,例如2-(N-吗啉代)-丙酸、N,N-二甲基-β-丙氨酸等等。非商用酸可以以简单明了的方式经由标准文献程序合成。
碳酸酯以及氨基甲酸酯前药可以以类似的方式制备。例如,氨基醇和二胺可以使用活化剂如光气或羰基二咪唑激活,以提供活化的碳酸酯,这进而可以与在此利用的化合物上的醇和/或酚羟基基团反应以提供碳酸酯和氨基甲酸酯前药。
可以用于或适合于制造本发明的化合物的不同保护基团和与其相关的合成方法可以改编自以下参考文献:特斯塔(Testa)等人,药物和前药代谢中的水解(Hydrolysis inDrug and Prodrug Metabolism),2003年6月,威利(Wiley)-VCH,苏黎世(Zurich),419-534和博蒙特(Beaumont)等人,最新药物代谢(Curr.Drug Metab.)2003,4:461-85。
此处提供了通过改编来自参考文献索博列夫(Sobolev)等人,2002,有机化学期刊(J.Org.Chem.)67:401-410的方法来合成酰氧基甲基版本的前药的方法。
R51是C1-C6烷基。
此处提供了用于通过改编来自参考文献曼泰拉(Mantyla)等人,2004,药物化学杂志(J.Med.Chem.)47:188-195的方法来合成膦酰基氧基甲基版本的前药的方法。
此处提供了合成烷基氧基甲基版本的前药的方法
R52是C1-C6烷基、C3-C8环烷基、C3-C9杂环基、C6-C10芳基、或C3-C9杂芳基。
实例
以下实例是出于说明本发明的各个实施例的目的而提供的,而且并非意在以任何方式限制本发明。这些实例连同在此所述的方法目前是优选实施例的代表,是示例性的,并且不旨在作为对本发明的范围的限制。本领域的普通技术人员会想到其中的变化以及如通过权利要求书的范围定义的本发明的精神内所涵盖的其他用途。
在以下这些实例以及贯穿本申请中,下列缩写具有以下含义。如果未被定义,那么这些术语具有其普遍接受的含义。
℃ = 摄氏度
RT = 室温
min = 分钟
h = 小时
μL = 微升
mL = 毫升
mmol = 毫摩尔
eq = 当量
mg = 毫克
ppm = 百万分之
atm = 大气压
MS = 质谱法
LC-MS = 液相层析–质谱法
HPLC = 高效液相层析法
NMR = 核磁共振
Sat./sat. = 饱和的
MeOH = 甲醇
EtOH = 乙醇
EtOAc = 乙酸乙酯
Et3N = 三乙胺
Ac2O = 乙酸酐
Na(OAc)3BH = 三乙酰氧基硼氢化钠
PBr3 = 三溴化磷
Ph3P = 三苯基膦
Ph3PBr2 = 三苯基膦二溴化物
CBr4 四溴甲烷
DMF = N,N-二甲基甲酰胺
DCM = 二氯甲烷
LAH/ = 氢化铝锂
LiAlH4
THF = 四氢呋喃
DIBAL = 氢化二异丁基铝
DIAD = 偶氮二甲酸二异丙酯
DEAD = 偶氮二甲酸二乙酯
DIPEA = N,N-二异丙基乙胺
Pd(dppf)Cl2 = [1,1′-双(二苯基膦基)二茂铁]二氯钯(II),络合物
以下代表性B-环以及C-环中间体可以通过本领域的普通技术人员通常已知的方法结合到本发明的化合物。
制备5-羟基-2-(2-甲氧基乙氧基)异烟碱醛).
步骤1
在0-5℃,向6-(苄氧基)吡啶-3-醇(2.0g,10mmol、1当量)在DMF(20mL)中的溶液中分批添加NaH(在矿物油中60%;0.6g,15mmol,1.5当量)。在添加完成时,继续将该混合物在0-5℃搅拌15min,添加氯甲基甲醚(0.88g,11mmol,1.1当量),在0-5℃下再搅拌20min,并且用NH4Cl(饱和)溶液淬灭。将水层用EtOAc(3×20mL)萃取,并且将合并的有机层用水和盐水进行洗涤,经Na2SO4干燥,浓缩,并且在硅胶上使用25%EtOAc/己烷作为洗脱液进行纯化以给出呈无色油状的2-(苄氧基)-5-(甲氧基甲氧基)吡啶(2.1g,87%)。MS(ESI)m/z 246.1[M+H]+。
步骤2
向在EtOH中的2-(苄氧基)-5-(甲氧基甲氧基)吡啶(1.8g,8.71mol)中添加Pd/C(1.0g)。将该混合物填充以H2(15psi),在室温搅拌45min,过滤,并且进行浓缩以给出呈淡黄色固体状的5-(甲氧基甲氧基)吡啶-2-醇(1.35g,定量产率)。MS(ESI)m/z 156.1[M+H]+。
步骤3
向5-(甲氧基甲氧基)吡啶-2-醇(1.35g,8.71mmol,1当量)和K2CO3(6.01g,43.6mmol,5.0当量)在DMF(30.0mL)中的混合物中添加1-溴-2-甲氧基乙烷(3.61g,26.1mmol,3当量)。将该混合物在60℃下加热2h,冷却,过滤,浓缩,并且在硅胶上使用EtOAc与己烷的混合物作为洗脱液进行纯化以给出呈无色油状的2-(2-甲氧基乙氧基)-5-(甲氧基甲氧基)吡啶(500mg,27%)。1H NMR(400MHz,CDCl3)δ7.94(d,J=3.0Hz,1H),7.35(ddd,J=8.9,3.0,1.0Hz,1H),6.76(dd,J=8.9,1.0Hz,1H),5.11(s,2H),4.48–4.40(m,2H),3.79-3.71(m,2H),3.50(s,3H),3.45(s,3H).MS(ESI)m/z 214.1[M+H]+。
步骤4
在-40℃,向2-(2-甲氧基乙氧基)-5-(甲氧基甲氧基)吡啶(1.34g,6.3mol,1当量)和二异丙胺(17.5uL,0.13mmol,0.02当量)在THF(50mL)中的混合物里添加甲基锂(1.6M/THF,7mL,11.3mol,1.8当量)。在添加完成时,将该混合物加温至0℃,继续在0℃搅拌3h,冷却回-40℃,并且缓慢添加DMF(0.83mL,11.3mol,1.8当量)。然后将该混合物在-40℃搅拌1h,用HCl(12N,12mL)和THF(28mL)的混合物淬灭,加温至室温,并且添加水(20mL)。用固体K2CO3将该混合物的pH调节至pH 8-9。将水层用EtOAc(30mL)萃取两次。将合并的有机层经Na2SO4干燥,浓缩,并且在硅胶上使用EtOAc与己烷的混合物作为洗脱液进行纯化以给出呈淡黄色油状的2-(2-甲氧基乙氧基)-5-(甲氧基甲氧基)异烟碱醛和2-(2-甲氧基乙氧基)-5-(甲氧基甲氧基)烟碱醛的混合物(5/1,1.27g,83.6%)。1H NMR(400MHz,CDCl3)δ10.45(s,1H),8.23(s,1H),7.16(s,1H),5.27(s,2H),4.46(dd,J=5.4,3.9Hz,2H),4.14(q,J=7.1Hz,1H),3.77–3.71(m,2H),3.56(s,3H),3.46(s,3H)and 1H NMR(400MHz,CDCl3)δ10.41(s,1H),8.18(d,J=3.2Hz,1H),7.85(d,J=3.1Hz,1H),5.16(s,2H),4.64–4.57(m,2H),3.85–3.79(m,J=5.4,4.0Hz,2H),3.50(s,3H),3.46(s,3H);MS(ESI)m/z 242.1[M+H]+。
步骤5
向2-甲氧基-5-(甲氧基甲氧基)异烟碱醛(1.27g,5.29mol)在THF(5mL)中的溶液里添加HCl(3N,4mL)。将该反应在50℃搅拌1h,冷却至室温并且用水(5mL)稀释。将该混合物用固体K2CO3中和至pH 7-8并且用EtOAc(100mL)萃取该水层两次。将合并的有机层经Na2SO4干燥,浓缩,并且在硅胶上使用EtOAc与己烷的混合物进行纯化,以给出5-羟基-2-(2-甲氧基乙氧基)异烟碱醛(630mg,60%)和5-羟基-2-(2-甲氧基乙氧基)烟碱醛(120mg,11%)。5-羟基-2-(2-甲氧基乙氧基)异烟碱醛的数据:1H NMR(400MHz,CDCl3)δ9.98(s,1H),9.50(s,1H),8.07(s,1H),7.02(s,1H),4.51–4.39(m,2H),3.81–3.72(m,2H),3.47(s,3H).LRMS(M+H+)m/z 198.1.5-羟基-2-(2-甲氧基乙氧基)烟碱醛的数据:1H NMR(400MHz,CDCl3)δ10.3(s,1H),7.99(d,J=3.2Hz,1H),7.58(d,J=3.2Hz,1H),7.18–7.07(br,1H),4.54(dd,J=5.4,3.7Hz,2H),3.84(dd,J=5.4,3.7Hz,2H),3.49(s,3H);MS(ESI)m/z 198.1[M+H]+。
制备2,6-二羟基苯甲醛.
向3000-mL三颈圆底烧瓶中放置AlCl3(240g,1.80mol,3.00当量)在二氯甲烷(1200mL)中的溶液。在0℃,将2,6-二甲氧基苯甲醛(100g,601.78mmol,1.00当量)在二氯甲烷(800ml)中的溶液逐滴添加到该反应混合物中。将所得溶液在室温下搅拌过夜,并且然后将其用200mL的稀释HCl(2M)淬灭。将所得溶液用2×200mL的二氯甲烷萃取。将合并的有机层在真空下浓缩。将残余物施加至硅胶柱(以乙酸乙酯/石油醚(1:200-1:50)作为洗脱液)以供应呈黄色固体状的40g(48%)的2,6-二羟基苯甲醛。
1HNMR(300MHz,DMSO-d6)δ11.25(s,2H),10.25(s,1H),7.36(m,1H),6.36(d,J=8.4Hz 2H);MS(ESI)m/z 139[M+H]+。
制备5-羟基-2-甲氧基异烟碱醛.
步骤1:在0-5℃,向6-甲氧基吡啶-3-醇(20g,0.16mol)在DMF(200mL)中的溶液里分批添加NaH(在矿物油中60%;9.6g,0.24mol)。在添加完成时,将该混合物继续在0-5℃搅拌15min,随后添加氯甲基甲醚。将该混合物在0-5℃再搅拌20min并且用水性NH4Cl(饱和)淬灭。将水层用EtOAc(3×100mL)萃取并且将合并的有机层用水和盐水进行洗涤,经Na2SO4干燥并在减压下进行浓缩。将残余物在硅胶上用25%EtOAc/己烷作为洗脱液进行纯化以给出呈无色油状的2-甲氧基-5-(甲氧基甲氧基)吡啶(24.1g,89.3%)。1H NMR(400MHz;CDCl3)7.97(d,1H),7.35(dd,1H),6.70(d,1H),5.12(s,2H),3.91(s,3H),3.51(s,3H);MS(ESI)m/z170.1[M+H]+。
步骤2:在-40℃,向2-甲氧基-5-(甲氧基甲氧基)吡啶(30g,0.178mol)和二异丙胺(507uL,3.6mmol)在THF(500mL)中的混合物里添加甲基锂(1.6M/THF,200mL,0.32mol)。在添加完成时,将该混合物加温至0℃并且在0℃继续搅拌3h。然后将该反应混合物冷却回-40℃,随后缓慢添加DMF(24.7mL,0.32mol)。然后将该混合物在-40℃搅拌1h并且用HCl(12N,120mL)和THF(280mL)的混合物进行淬灭。添加水(200mL)并且将该混合物的pH用固体K2CO3调节至pH 8-9。将该混合物用EtOAc(300mL)萃取两次。将有机层合并,经Na2SO4干燥,并且进行浓缩以给出呈棕色固体状的2-甲氧基-5-(甲氧基甲氧基)异烟碱醛(33.5g,95.7%),将其用于下一步骤而不经进一步纯化。1H NMR(400MHz;CD3OD)7.90(s,1H),6.92(s,1H),5.64(s,1H),5.20(s,2H),3.84(s,3H),3.48(s,3H);MS(ESI)m/z 198.1[M+H]+。
步骤3:向2-甲氧基-5-(甲氧基甲氧基)异烟碱醛(33.5g,0.17mol)在THF(150mL)中的溶液里添加HCl(3N,250mL)。将该反应在50℃搅拌1h,冷却至室温,并且用水(500mL)稀释。将该混合物用固体K2CO3中和至pH 7-8。收集淡黄色固体,将其用水洗涤,并且在真空烘箱中(40℃)干燥过夜,以给出5-羟基-2-甲氧基异烟碱醛(17.9g,74.6%)。1H NMR(400MHz;DMSO)=10.31(s,1H),8.03(s,1H),6.89(s,1H),3.80(s,3H);MS(ESI)m/z154.0[M+H]+。
GBT915
(S)-2-((1-苯甲酰基吡咯烷-2-基)甲氧基)-6-羟基苯甲醛
GBT915-(S)-2-((1-苯甲酰基吡咯烷-2-基)甲氧基)-6-羟基苯甲醛。
步骤1:在0℃向(S)-吡咯烷-2-基甲醇(700mg,6.92mmol)和DIPEA(1.20mL,6.92mmol)在DCM(12ml)中的溶液中添加苯甲酰氯(0.80mL,6.92mmol),30min之后,将其用更多DCM稀释,并且将其用饱和NaHCO3、盐水洗涤,经MgSO4干燥,浓缩以给出粗产物,将其通过柱(EtOAc 0-100%)纯化,以给出(S)-(2-(羟基甲基)吡咯烷-1-基)(苯基)甲酮(1.2g)。
步骤2:在室温向(S)-(2-(羟基甲基)吡咯烷-1-基)(苯基)甲酮(100mg,0.49mmol)和2,6-二羟基苯甲醛(90mg,0.64mmol)在THF(1mL)中的溶液中添加PPh3(190mg,0.73mmol)和DIAD(0.15mL,0.73mmol),30min之后,将其浓缩,并且将残余物通过柱(己烷/EtOAc=100:0至1:1)纯化,以给出(S)-2-((1-苯甲酰基吡咯烷-2-基)甲氧基)-6-羟基苯甲醛(65mg)。1H NMR(400MHz,氯仿-d)δ11.90(s,1H),10.40(s,1H),7.51–7.31(m,6H),6.53(t,J=9.2Hz,2H),4.65(s,1H),4.38(d,J=6.1Hz,2H),3.51(t,J=6.8Hz,2H),2.29–1.90(m,2H),1.79(d,J=36.4Hz,1H),1.31–1.18(m,1H).MS针对C19H19NO4发现:326.5。
GBT952
(S)-2-((1-苯甲酰基哌啶-2-基)甲氧基)-6-羟基苯甲醛
GBT952-(S)-2-((1-苯甲酰基哌啶-2-基)甲氧基)-6-羟基苯甲醛
步骤1:在室温向(S)-哌啶-2-基甲醇盐酸盐(0.11g,0.70mmol)在DCM(2mL)中的悬浮液中添加DIPEA(0.27mL,1.54mmol)和苯甲酰氯(0.08mL,0.70mmol),在搅拌30min之后,将其用DCM稀释并且用饱和NH4Cl、盐水洗涤,经MgSO4干燥,并且浓缩以给出粗产物,将其通过柱(己烷/EtOAc=0:100)纯化,以给出(S)-(2-(羟基甲基)哌啶-1-基)(苯基)甲酮(84mg)。
步骤2:在0℃向2,6-二羟基苯甲醛(110mg,0.80mmol)和(S)-(2-(羟基甲基)哌啶-1-基)(苯基)甲酮(0.23g,1.04mmol)在THF(1.5mL)中的溶液中添加PPh3(310mg,1.20mmol)和DIAD(0.23mL,1.20mmol),然后将它加温至室温并搅拌1h。将该混合物浓缩并且通过柱(己烷/EtOAc=60:40)纯化,以给出(S)-2-((1-苯甲酰基哌啶-2-基)甲氧基)-6-羟基苯甲醛62mg。1H NMR(400MHz,氯仿-d)δ11.98(s,1H),10.29(s,1H),7.45-7.28(m,5H),6.58-6.50(m,2H),6.40(dt,J=8.1,0.8Hz,1H),4.32(t,J=8.5Hz,1H),4.18(s,1H),3.04(s,1H),1.94–1.76(m,3H),1.73–1.58(m,3H),1.26(dt,J=7.0,3.1Hz,2H).MS针对C20H21NO4发现:340.2。
GBT961
(S)-2-羟基-6-((1-烟酰基吡咯烷-2-基)甲氧基)苯甲醛
GBT961-(S)-2-羟基-6-((1-烟酰基吡咯烷-2-基)甲氧基)苯甲醛
步骤1:在0℃向(S)-吡咯烷-2-基甲醇(500mg,4.94mmol)在DCM(10mL)中的溶液中添加DIPEA(1.89mL,10.87mmol),随后添加烟酰氯(0.92g,5.19mmol),在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并浓缩以给出粗产物,将其通过柱(DCM/MeOH=100:0至80:20)纯化,以给出(S)-(2-(羟基甲基)吡咯烷-1-基)(吡啶-3-基)甲酮(900mg)。
步骤2:在0℃向(S)-(2-(羟基甲基)吡咯烷-1-基)(吡啶-3-基)甲酮(150mg,0.73mmol)和2,6-二羟基苯甲醛(0.13g,0.91mmol)在THF(1.5mL)中的溶液中添加PPh3(0.29g,1.1mmol)和DIAD(0.21mL,1.1mmol),并且在室温下搅拌2h,随后将其浓缩,将所得残余物通过柱(己烷/EtOAc=100:0至40:60至DCM/MeOH=100:0至90:10)纯化,以给出产物的混合物,将其进一步通过制备型HPLC纯化,以给出(S)-2-羟基-6-((1-烟酰基吡咯烷-2-基)甲氧基)苯甲醛(68mg)。1H NMR(400MHz,氯仿-d)δ11.90(s,1H),10.40(s,1H),8.78–8.72(m,1H),8.68(dd,J=4.9,1.7Hz,1H),7.82(dt,J=7.9,2.0Hz,1H),7.40(t,J=8.3Hz,1H),7.36(ddd,J=7.9,4.9,0.9Hz,1H),6.53(dd,J=8.5,4.9Hz,2H),4.66(d,J=11.1Hz,1H),4.38(d,J=5.8Hz,2H),3.54(t,J=7.6Hz,2H),2.26(dtd,J=12.8,7.6,5.3Hz,1H),2.19–2.10(m,1H),2.10–1.98(m,1H),1.88(dt,J=12.5,7.8Hz,1H).MS针对C18H18N2O4发现:327.4。
GBT962
(S)-2-羟基-6-((1-异烟酰基吡咯烷-2-基)甲氧基)苯甲醛
GBT962-(S)-2-羟基-6-((1-异烟酰基吡咯烷-2-基)甲氧基)苯甲醛
步骤1:在0℃向(S)-吡咯烷-2-基甲醇(500mg,4.94mmol)在DCM(10mL)中的溶液中添加DIPEA(1.89mL,10.87mmol),随后添加烟酰氯(0.88g,4.94mmol),在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并浓缩以给出粗产物,将其通过柱(DCM/MeOH=100:0至80:20)纯化,以给出(S)-(2-(羟基甲基)吡咯烷-1-基)(吡啶-4-基)甲酮(900mg)。
步骤2:在0℃向(S)-(2-(羟基甲基)吡咯烷-1-基)(吡啶-3-基)甲酮(150mg,0.73mmol)和2,6-二羟基苯甲醛(0.13g,0.91mmol)在THF(1.5mL)中的溶液中添加PPh3(0.29g,1.1mmol)和DIAD(0.21mL,1.1mmol),并且在室温下搅拌2h,随后将其浓缩,将所得残余物通过柱(己烷/EtOAc=100:0至40:60至DCM/MeOH=100:0至90:10)纯化,以给出产物的混合物,将其进一步通过制备型HPLC纯化,以给出(S)-2-羟基-6-((1-异烟酰基吡咯烷-2-基)甲氧基)苯甲醛(36mg)。1H NMR(400MHz,氯仿-d)δ11.88(s,1H),10.38(s,1H),8.72–8.63(m,2H),7.39(t,J=8.4Hz,1H),7.35–7.24(m,2H),6.52(t,J=8.6Hz,2H),4.63(dq,J=8.4,5.1Hz,1H),4.42–4.29(m,2H),3.46(七重峰,J=6.3,5.4Hz,2H),2.24(dtd,J=13.3,7.7,5.5Hz,1H),2.13(dq,J=13.0,6.8Hz,1H),2.03(dt,J=12.4,6.3Hz,1H),1.95–1.79(m,1H).MS针对C18H18N2O4发现:327.4。
GBT979
(S)-2-羟基-6-((1-吡啶甲酰基吡咯烷-2-基)甲氧基)苯甲醛
GBT979-(S)-2-羟基-6-((1-吡啶甲酰基吡咯烷-2-基)甲氧基)苯甲醛
步骤1:在0℃向(S)-吡咯烷-2-基甲醇(500mg,4.94mmol)在DCM(10mL)中的溶液中添加DIPEA(1.89mL,10.87mmol),随后添加异烟酰氯(0.88g,4.94mmol),在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并浓缩以给出粗产物,将其通过柱(DCM/MeOH=100:0至80:20)纯化,以给出(S)-(2-(羟基甲基)吡咯烷-1-基)(吡啶-2-基)甲酮(900mg)。
步骤2:在室温向(S)-(2-(羟基甲基)吡咯烷-1-基)(吡啶-2-基)甲酮(100mg,0.48mmol)和2,6-二羟基苯甲醛(0.08g,0.6mmol)在THF(5mL)的溶液中添加PPh3(聚合物负载,600mg,0.72mmol)和DIAD(0.15mL,0.72mmol)。在室温搅拌3h之后,将该混合物用AcCN稀释,将不溶材料过滤掉,将滤液浓缩,以给出粗产物,将其通过制备型HPLC进行纯化以给出(S)-2-羟基-6-((1-吡啶甲酰基吡咯烷-2-基)甲氧基)苯甲醛(15mg)。1H NMR(400MHz,氯仿-d)δ11.92(s,1H),10.39(d,J=0.6Hz,1H),8.55(ddt,J=40.7,4.9,1.1Hz,1H),7.89–7.74(m,2H),7.40(t,J=8.4Hz,1H),7.37–7.23(m,1H),6.60–6.46(m,2H),4.76–4.65(m,1H),4.48(dd,J=9.5,3.3Hz,1H),4.32–4.18(m,1H),3.99–3.81(m,1H),3.81–3.67(m,1H),2.25–1.83(m,4H).MS针对C18H18N2O4发现:327.3。
GBT1064
(S)-2-羟基-6-((1-(1-异丙基-1H-吡唑-5-羰基)吡咯烷-2-基)甲氧基)苯甲醛
GBT1064-(S)-2-羟基-6-((1-(1-异丙基-1H-吡唑-5-羰基)吡咯烷-2-基)甲氧基)苯甲醛
步骤1:向(S)-吡咯烷-2-基甲醇(100mg,1mmol)和1-异丙基-1H-吡唑-5-甲酸(0.15g,1mmol)在DMF(2mL)中的溶液中添加HATU(0.38g,1mmol),并且然后将该混合物进行搅拌直至完成,将其用水稀释并用EtOAc萃取,将有机层干燥并浓缩以给出粗产物,将其通过柱(100%EtOAc)纯化,以给出(S)-(2-(羟基甲基)吡咯烷-1-基)(1-异丙基-1H-吡唑-5-基)甲酮(120mg)。
步骤2:在0℃向(S)-(2-(羟基甲基)吡咯烷-1-基)(1-异丙基-1H-吡唑-5-基)甲酮(120mg,0.51mmol)和2,6-二羟基苯甲醛(0.09g,0.66mmol)在THF(4mL)的溶液中添加PPh3(聚合物负载,640mg,0.77mmol)和DIAD(0.16mL,0.77mmol)。在室温搅拌1h之后,将其用AcCN稀释,将不溶材料过滤掉并且将滤液浓缩,以给出粗产物,将其通过制备型HPLC进行纯化以给出(S)-2-羟基-6-((1-(1-异丙基-1H-吡唑-5-羰基)吡咯烷-2-基)甲氧基)苯甲醛(46mg)。1H NMR(400MHz,氯仿-d)δ11.90(s,1H),10.37(s,1H),7.55(d,J=2.0Hz,1H),7.41(t,J=8.4Hz,1H),6.54(d,J=8.5Hz,1H),6.48(d,J=8.3Hz,1H),6.37(d,J=2.0Hz,1H),5.03–4.94(m,1H),4.65(s,1H),4.37(d,J=5.4Hz,2H),3.67(s,1H),3.60–3.45(m,1H),2.25(dd,J=13.1,6.1Hz,1H),2.11(ddt,J=30.4,12.0,6.4Hz,2H),1.93(s,1H),1.53(d,J=6.6Hz,3H),1.46(d,J=6.7Hz,3H).MS(M+H)针对C19H23N3O4发现:358.3。
GBT1118
(S)-2-羟基-6-((1-烟酰基哌啶-2-基)甲氧基)苯甲醛
GBT1118-(S)-2-羟基-6-((1-烟酰基哌啶-2-基)甲氧基)苯甲醛
步骤1&2:向(S)-叔-丁基2-(羟基甲基)哌啶-1-甲酸酯(215mg,1.02mmol)的固体样品中添加在二噁烷(1mL)中的4N HCl。在搅拌30min之后,将其浓缩,以给出(S)-哌啶-2-基甲醇HCl盐。在0℃向(S)-哌啶-2-基甲醇HCl盐在DCM(3mL)中的悬浮液中添加DIPEA(0.39mL,2.24mmol)和烟酰氯(0.2g,1.12mmol)。A在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过柱(DCM/MeOH=90:10)纯化,以给出(S)-(2-(羟基甲基)哌啶-1-基)(吡啶-3-基)甲酮(130mg)。
步骤2:在0℃向(S)-(2-(羟基甲基)哌啶-1-基)(吡啶-3-基)甲酮(130mg,0.59mmol)和2,6-二羟基苯甲醛(0.11g,0.77mmol)在THF(4mL)中的溶液中添加PPh3(聚合物负载,0.74g,0.89mmol)和DIAD(0.17mL,0.89mmol),并且在室温下搅拌2h,随后将其浓缩,将所得残余物通过制备型HPLC纯化以给出(S)-2-羟基-6-((1-烟酰基哌啶-2-基)甲氧基)苯甲醛(30mg)。1H NMR(400MHz,氯仿-d)δ11.95(s,1H),10.29(s,1H),8.66(dd,J=4.9,1.7Hz,1H),8.65–8.62(m,1H),7.73(dt,J=7.8,2.0Hz,1H),7.41(d,J=8.4Hz,1H),7.37(ddd,J=7.8,4.9,0.9Hz,1H),6.59–6.54(m,1H),6.40(d,J=7.0Hz,1H),4.39–4.30(m,2H),4.19(s,2H),3.15(s,1H),1.97–1.78(m,4H),1.72–1.56(m,2H).MS针对C19H20N2O4发现:341.3。
GBT001579
(S)-2-羟基-6-((1-(6-甲基烟酰基)哌啶-2-基)甲氧基)苯甲醛
GBT1579-(S)-2-羟基-6-((1-(6-甲基烟酰基)哌啶-2-基)甲氧基)苯甲醛
步骤1&2:在0℃向6-甲基烟酸(270mg,2mmol)在DCM(5mL)中的悬浮液中添加草酰氯(0.34mL,4mmol),随后添加一滴DMF,在室温搅拌2小时之后,将该溶液浓缩以给出粗的酰氯。
在0℃向在DCM(4mL)中的以上粗的酰氯中添加(S)-哌啶-2-基甲醇盐酸盐(300mg,1.98mmol)和DIPEA(1.04mL,5.94mmol),在室温下搅拌2h之后,添加更多DIPEA以驱动该反应完成。将该反应用DCM稀释,用饱和NaHCO3、盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过柱(DCM/MeOH=90:10)纯化,以给出所希望的(S)-(2-(羟基甲基)哌啶-1-基)(6-甲基吡啶-3-基)甲酮(100mg)。
步骤3:在0℃向(S)-(2-(羟基甲基)哌啶-1-基)(6-甲基吡啶-3-基)甲酮(100mg,0.43mmol)和2,6-二羟基苯甲醛(80mg,0.56mmol)在THF(2.5mL)中的溶液中添加聚合物负载的三苯基膦(435mg,0.52mmol)和DIAD(0.11mL,0.52mmol),在室温搅拌4小时之后,将该溶液过滤,将滤液浓缩并且通过制备型HPLC纯化,以给出(S)-2-羟基-6-((1-(6-甲基烟酰基)哌啶-2-基)甲氧基)苯甲醛(29mg)。1H NMR(400MHz,氯仿-d)δ11.95(s,1H),10.28(s,1H),8.53(d,J=2.2Hz,1H),7.62(dd,J=8.0,2.3Hz,1H),7.39(t,J=8.4Hz,1H),7.21(d,J=8.0Hz,1H),6.55(dd,J=8.5,0.8Hz,1H),6.40(s,1H),4.33(t,J=8.6Hz,2H),4.19(s,1H),3.09(s,2H),2.59(s,3H),1.73(m,6H).MS(M+H)针对C20H22N2O4发现:355.3。
GBT001580
(S)-2-羟基-6-((1-(2-甲基烟酰基)哌啶-2-基)甲氧基)苯甲醛
GBT1580-(S)-2-羟基-6-((1-(2-甲基烟酰基)哌啶-2-基)甲氧基)苯甲醛
步骤1&2:在0℃向2-甲基烟酸(300mg,2.19mmol)在DCM(5mL)中的悬浮液中添加草酰氯(0.28mL,3.3mmol),并进一步在室温搅拌2小时,然后将该溶液浓缩以给出粗的酰氯。
在0℃向在DCM(5mL)中的酰氯中添加(S)-哌啶-2-基甲醇盐酸盐(250mg,1.65mmol)和三乙胺(0.69mL,4.95mmol),并且进一步在室温搅拌30min,将该溶液用更多DCM稀释,并且将有机层用饱和NaHCO3和盐水进行洗涤,干燥并且浓缩,以给出粗产物,将其通过柱(DCM/MeOH=95:5)纯化,以给出(S)-(2-(羟基甲基)哌啶-1-基)(2-甲基吡啶-3-基)甲酮(200mg)。
步骤3:在0℃向(S)-(2-(羟基甲基)哌啶-1-基)(2-甲基吡啶-3-基)甲酮(180mg,0.77mmol)和2,6-二羟基苯甲醛(140mg,1.0mmol)在THF(5mL)中的溶液中添加聚合物负载的三苯基膦(1.0g,1.16mmol)和DIAD(0.21mL,1.08mmol),在室温搅拌15小时之后,将该溶液过滤,将滤液浓缩并且通过制备型HPLC纯化,以给出(S)-2-羟基-6-((1-(2-甲基烟酰基)哌啶-2-基)甲氧基)苯甲醛(129mg)。1H NMR(400MHz,氯仿-d)δ11.99(s,1H),10.40(s,1H),8.53(m,1H),7.42(t,J=8.4Hz,1H),7.32(m,1H),7.20(m,1H),6.56(d,J=8.4Hz,1H),6.47(d,J=8.3Hz,1H),5.39(s,1H),4.38(t,J=8.8Hz,1H),4.21(dd,J=9.5,6.6Hz,1H),3.36(d,J=13.5Hz,1H),3.14(m,1H),2.52(s,3H),2.10–1.35(m,6H).MS(M+H)针对C20H22N2O4发现:355.3。
GBT1124
(S)-2-((4-苯甲酰基吗啉-3-基)甲氧基)-6-羟基苯甲醛
GBT1124-(S)-2-((4-苯甲酰基吗啉-3-基)甲氧基)-6-羟基苯甲醛
步骤1&2:向(R)-叔-丁基3-(羟基甲基)吗啉-4-甲酸酯(150mg,0.69mmol)的固体样品中添加在二噁烷(1.5mL)中的4N HCl。在搅拌30min之后,将其浓缩,以给出作为HCl盐的(R)-(3-(羟基甲基)吗啉代)(苯基)甲酮。在0℃向(R)-(3-(羟基甲基)吗啉代)(苯基)甲酮HCl盐在DCM(2mL)中的悬浮液中添加DIPEA(0.36mL,2.07mmol)和苯甲酰氯(0.08mL,0.69mmol)。A在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过柱(100%EtOAc)纯化,以给出(R)-(3-(羟基甲基)吗啉代)(苯基)甲酮(120mg)。
步骤3.在0℃向(R)-(3-(羟基甲基)吗啉代)(苯基)甲酮(80mg,0.36mmol)和2,6-二羟基苯甲醛(0.06g,0.47mmol)在THF(2mL)中的溶液中添加PPh3(聚合物负载,0.45g,0.54mmol)和DIAD(0.11mL,0.54mmol),并且在室温下搅拌2h,随后将其浓缩,将所得残余物通过制备型HPLC纯化以给出(S)-2-((4-苯甲酰基吗啉-3-基)甲氧基)-6-羟基苯甲醛(20mg)。1H NMR(400MHz,氯仿-d)δ11.96(s,1H),10.28(s,1H),7.50–7.35(m,7H),6.61–6.41(m,1H),4.37(s,2H),4.07(s,1H),3.89(s,1H),3.76(dd,J=12.2,3.2Hz,1H),3.55(s,2H),3.39(s,1H),1.35–1.18(m,1H).MS针对C19H19NO5发现:342.3。
GBT1126
(S)-2-羟基-6-((1-(苯基磺酰基)吡咯烷-2-基)甲氧基)苯甲醛
GBT1126-(S)-2-羟基-6-((1-(苯基磺酰基)吡咯烷-2-基)甲氧基)苯甲醛
步骤1:在0℃向(S)-吡咯烷-2-基甲醇(500mg,4.94mmol)在DCM(10mL)中的溶液中添加TEA(1.04mL,7.41mmol),随后添加苯磺酰氯(0.63mL,4.94mmol)。A在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过柱纯化为(S)-(1-(苯基磺酰基)吡咯烷-2-基)甲醇。
步骤2:在0℃向(S)-(1-(苯基磺酰基)吡咯烷-2-基)甲醇(125mg,0.54mmol)和2,6-二羟基苯甲醛(0.1g,0.7mmol)在THF(2mL)中的溶液中添加PPh3(0.21g,0.81mmol)和DIAD(0.16mL,0.81mmol),并且在室温下搅拌2h,随后将其浓缩,将所得残余物通过制备型HPLC纯化以给出(S)-2-羟基-6-((1-(苯基磺酰基)吡咯烷-2-基)甲氧基)苯甲醛(37mg)。1HNMR(400MHz,氯仿-d)δ11.90(d,J=0.4Hz,1H),10.28(d,J=0.6Hz,1H),7.93–7.76(m,2H),7.65–7.56(m,1H),7.56–7.47(m,2H),7.43(td,J=8.4,0.4Hz,1H),6.55(dt,J=8.5,0.7Hz,1H),6.48(dd,J=8.3,0.8Hz,1H),4.42–4.31(m,1H),4.08–3.95(m,2H),3.56–3.45(m,1H),3.20(ddd,J=10.0,8.0,7.0Hz,1H),2.03–1.83(m,2H),1.81–1.50(m,2H).MS针对C18H19NO5S发现:362.4。
GBT1128
(S)-2-羟基-6-((1-(吡啶-3-基磺酰基)吡咯烷-2-基)甲氧基)苯甲醛
GBT1128-(S)-2-羟基-6-((1-(吡啶-3-基磺酰基)吡咯烷-2-基)甲氧基)苯甲醛
步骤1:在0℃向(S)-吡咯烷-2-基甲醇(320mg,3.16mmol)在DCM(6mL)中的溶液中添加TEA(0.97mL,6.95mmol),随后添加吡啶-3-磺酰氯(0.68g,3.16mmol)。A在搅拌30min之后,将其用DCM稀释,用水性饱和NaHCO3、盐水洗涤,干燥并且浓缩,以给出粗产物,将其通过柱纯化以给出(S)-(1-(吡啶-3-基磺酰基)吡咯烷-2-基)甲醇(66mg)。
步骤2:在0℃向(S)-(1-(吡啶-3-基磺酰基)吡咯烷-2-基)甲醇(65mg,0.29mmol)和2,6-二羟基苯甲醛(0.06g,0.41mmol)在THF(2mL)中的溶液中添加PPh3(聚合物负载,0.37g,0.44mmol)和DIAD(0.09mL,0.44mmol),并且在室温下搅拌2h,随后将其用AcCN稀释,将不溶材料过滤掉,将滤液浓缩,将所得残余物通过制备型HPLC纯化以给出(S)-2-羟基-6-((1-(吡啶-3-基磺酰基)吡咯烷-2-基)甲氧基)苯甲醛(17mg)。1H NMR(400MHz,氯仿-d)δ11.90(s,1H),10.29(d,J=0.6Hz,1H),9.08(dd,J=2.3,0.9Hz,1H),8.83(dd,J=4.9,1.6Hz,1H),8.18–8.09(m,1H),7.53–7.46(m,1H),7.44(t,J=8.4Hz,1H),6.61–6.54(m,1H),6.50–6.44(m,1H),4.40–4.31(m,1H),4.12–3.96(m,2H),3.56(ddd,J=10.5,7.1,4.2Hz,1H),3.21(dt,J=10.1,7.4Hz,1H),2.08–1.88(m,2H),1.87–1.66(m,2H).MS(M+H)针对C17H18N2O5S发现:363.4。
由前文应理解的是,虽然用于说明的目的已经在此描述了本发明的特定实施例,但可以在不偏离本发明的精神和范围的情况下进行各种修改。
贯穿本发明的说明,参考了各种专利申请以及公开物,它们中每一篇均通过引用以其全文结合在此。
Claims (20)
1.一种具有化学式(I)的化合物
或其互变异构体,或其各自药学上可接受的盐或其药学上可接受的盐,其中
R3是C1-C6烷基、C3-C8环烷基、C1-C6烷氧基、C3-C8环烷氧基、或-NR1R2;
每个R1和R2独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-10元杂环或5-10元杂芳基,该杂环或杂芳基各自包含高达5个环杂原子,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中每个烷基、环烷基、杂环、芳基或杂芳基被任选取代,或R1和R2与它们附接的氮原子一起形成任选取代的4-7元杂环;或
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基、或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;或
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该–L1L2R3是α或β位取代的;
其中Z和–CV1V2H连接到环C上的相邻原子;
环C是任选取代的C6-C10芳基或任选取代的包含1-3个氮原子或N的氧化形式的5-10元杂芳基;或
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;并且
R19是氢或前药部分R;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
2.一种具有化学式(II)的化合物
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C1-C6烷基、C3-C8环烷基、C1-C6烷氧基、C3-C8环烷氧基、或-NR1R2;
每个R1和R2独立地是氢、C1-C6烷基、C3-C8环烷基、C6-C10芳基、4-10元杂环或5-10元杂芳基,该杂环或杂芳基各自包含高达5个环杂原子,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中每个烷基、环烷基、杂环、芳基或杂芳基被任选取代,或R1和R2与它们附接的氮原子一起形成任选取代的4-7元杂环;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
环B是任选取代的C6-C10芳基、任选取代的具有1-3个氮原子或N的氧化形式的5-10元杂芳基、或任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该–LCOR3是α或β位取代的;
环C是任选取代的C6-C10芳基或任选取代的包含1-3个氮原子或N的氧化形式的5-10元杂芳基;
其中Z和–CV1V2H连接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基;
R4是OH、卤素、C1-C6烷氧基、C3-C6环烷氧基或O-R,其中R是前药部分,其中该C1-C6烷氧基任选地被1-5个卤素取代。
5.如权利要求4所述的化合物,其中R4和–CHO连接到环C上的相邻原子。
8.如权利要求3-7中任一项所述的化合物,其中环B被1-3个以下项取代:卤素、C1-C6烷基、COR15、或COOR15;并且
R15是C1-C6烷基、C6-C10芳基、包含高达5个环杂原子的5-10元杂芳基或4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代。
9.如权利要求3所述的化合物,其中该化合物是选自下组,该组由以下各项组成:
或其N氧化物,其中
每个P和Q独立地是选自CHR17、NCOR15、NCO2R15;N-O、O、S、SO、以及SO2;
每个R1和R2独立地是氢、C1-C6烷基、C6-C10芳基、5-10元杂芳基或包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代;
R15是C1-C6烷基、C6-C10芳基、包含高达5个环杂原子的5-10元杂芳基或4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代;
R17是C1-C6烷基、C6-C10芳基、包含高达5个环杂原子的5-10元杂芳基或4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,其中该烷基、芳基、杂芳基或杂环基被任选地取代;
并且r是0、1、或2。
10.如权利要求1所述的化合物,该化合物具有化学式(IV)
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
每个Y和Z独立地是CR10R11、O、S、SO、SO2、或NR10;每个R10和R11独立地是氢或任选地被1-3个卤素、OH、或C1-C6烷氧基取代的C1-C3烷基,或CR10R11是C=O,其条件是如果Y和Z中一项是O、S、SO、SO2,则另一项不是CO,并且Y和Z都不是杂原子或其氧化形式;
其中Y相对于该–L1L2R1是α或β位取代的;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
R19是氢或前药部分R;并且
其中Z和–CV1V2H附接到环C上的相邻原子;
V1和V2独立地是C1-C6烷氧基;或V1和V2连同它们附接至其上的碳原子一起形成具有以下化学式的环:
其中每个V3和V4独立地是O、S、或NH,其条件是当V3和V4中一项是S时,另一项是NH,并且其条件是V3和V4都不是NH;q是1或2;每个V5独立地是C1-C6烷基或CO2R60,其中每个R60独立地是C1-C6烷基或氢;t是0、1、2、或4;或CV1V2是C=V,其中V是O、NOR80、或NNR81R82;
R80是任选取代的C1-C6烷基;
R81和R82独立地选自下组,该组由以下各项组成:氢;任选取代的C1-C6烷基、COR83和CO2R84;
R83是氢或任选取代的C1-C6烷基;并且
R84是任选取代的C1-C6烷基。
11.如权利要求10所述的化合物,该化合物具有化学式(V):
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
Z是O、S、SO或SO2;
环C是C6-C10芳基或包含高达5个环杂原子的5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式,该芳基或杂芳基各自任选地被1-4个以下项取代:卤素、氧代、-OR19、C1-C6烷基、和/或C1-C6烷氧基,其中该C1-C6烷基任选地被1-5个卤素、C1-C6烷氧基和/或包含高达5个环杂原子的4-10元杂环取代,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;并且
R19是氢或前药部分R。
12.如权利要求10所述的化合物,该化合物具有化学式(VI):
或其互变异构体,或其各自药学上可接受的盐,其中
R3是C6-C10芳基、或5-10元杂芳基,其中该杂原子选自下组,该组由以下各项组成:O、N、S、以及N和S的氧化形式,其中该芳基或杂芳基各自任选地被1-4个C1-C6烷基取代;
L1是键或是NR70、O、S、或(CR71R72)d;其中每个R70、R71、以及R72独立地是氢或C1-C6烷基;
d是1、2、或3;
L2是C=O或SO2;
环B是任选取代的包含高达5个环杂原子的4-10元杂环,其中该杂原子选自下组,该组由以下各项组成:O、N、S以及N和S的氧化形式;
R4是-OR19或C1-C6烷氧基;并且
R19是氢或前药部分R。
15.如权利要求10-14中任一项所述的化合物,其中L1是键并且L2是C=O或SO2。
18.一种组合物,该组合物包括如权利要求3-9和11-17中任一项所述的化合物以及至少一种药学上可接受的赋形剂。
19.一种用于增加受试者体内血红蛋白S的氧亲和力的方法,该方法包括向对其有需要的受试者给予治疗有效量的如权利要求3-9和11-17中任一项所述的化合物或如权利要求18所述的组合物。
20.一种用于治疗与镰状细胞性贫血相关的缺氧的方法,该方法包括向对其有需要的受试者给予治疗有效量的如权利要求3-9和11-17中任一项所述的化合物或如权利要求18所述的组合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/815,735 US8952171B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
US13/815,735 | 2013-03-15 | ||
US201361905803P | 2013-11-18 | 2013-11-18 | |
US61/905,803 | 2013-11-18 | ||
CN201480015944.4A CN105073728A (zh) | 2013-03-15 | 2014-03-10 | 化合物及其用于调节血红蛋白的用途 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480015944.4A Division CN105073728A (zh) | 2013-03-15 | 2014-03-10 | 化合物及其用于调节血红蛋白的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112500338A true CN112500338A (zh) | 2021-03-16 |
Family
ID=51580732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480015944.4A Withdrawn CN105073728A (zh) | 2013-03-15 | 2014-03-10 | 化合物及其用于调节血红蛋白的用途 |
CN202010996640.8A Pending CN112500338A (zh) | 2013-03-15 | 2014-03-10 | 化合物及其用于调节血红蛋白的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480015944.4A Withdrawn CN105073728A (zh) | 2013-03-15 | 2014-03-10 | 化合物及其用于调节血红蛋白的用途 |
Country Status (22)
Country | Link |
---|---|
US (3) | US20160083343A1 (zh) |
EP (1) | EP2970196B1 (zh) |
JP (3) | JP6426694B2 (zh) |
KR (1) | KR102280614B1 (zh) |
CN (2) | CN105073728A (zh) |
AP (1) | AP2015008721A0 (zh) |
AU (3) | AU2014237340C1 (zh) |
BR (1) | BR112015021985B1 (zh) |
CA (1) | CA2903220C (zh) |
CL (1) | CL2015002501A1 (zh) |
EA (1) | EA034922B1 (zh) |
ES (1) | ES2852054T3 (zh) |
IL (1) | IL241060B (zh) |
MX (1) | MX2015011445A (zh) |
MY (1) | MY191087A (zh) |
PE (1) | PE20161035A1 (zh) |
SA (2) | SA517382253B1 (zh) |
SG (2) | SG11201507320QA (zh) |
TW (1) | TWI695830B (zh) |
UY (1) | UY35426A (zh) |
WO (1) | WO2014150268A1 (zh) |
ZA (1) | ZA201703791B (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
CA2860323C (en) | 2011-12-28 | 2022-03-08 | The Regents Of The University Of California | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
AU2014237348C1 (en) | 2013-03-15 | 2019-02-07 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20160083343A1 (en) * | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
MY189995A (en) | 2014-02-07 | 2022-03-22 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2016043849A2 (en) * | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
WO2020072377A1 (en) * | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
MD3880654T2 (ro) * | 2018-11-19 | 2022-05-31 | Global Blood Therapeutics Inc | Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei |
MX2021006095A (es) | 2018-11-29 | 2021-07-06 | Pfizer | Pirazoles como moduladores de hemoglobina. |
EP4126832A1 (en) | 2020-03-31 | 2023-02-08 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535183A (en) * | 1980-12-18 | 1985-08-13 | Burroughs Wellcome Co. | Pharmaceutical compounds, preparation, use and intermediates therefor and their preparation |
Family Cites Families (434)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE276479C (zh) | ||||
DE226590C (zh) | ||||
DE258226C (zh) | ||||
NL218146A (zh) | 1956-02-13 | 1900-01-01 | ||
BE787580A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Procede de preparation de derives du furanne |
BE787576A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Derives de benzofuranne et leur utilisation comme azureurs optiques |
GB1409865A (en) | 1973-02-13 | 1975-10-15 | Science Union & Cie | Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them |
GB1593417A (en) | 1976-12-22 | 1981-07-15 | Squibb & Sons Inc | Carbocyclic-fused pyrazolopyridine derivatives |
US4062858A (en) | 1976-12-22 | 1977-12-13 | E. R. Squibb & Sons, Inc. | Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines |
DE2964427D1 (en) | 1978-10-04 | 1983-02-03 | Ciba Geigy Ag | Process for the preparation of furanyl-benzazoles |
DE2853765A1 (de) | 1978-12-13 | 1980-06-26 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuranen |
DE2904829A1 (de) | 1979-02-08 | 1980-08-14 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuran |
ZA803880B (en) * | 1979-06-29 | 1982-02-24 | Wellcome Found | Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation |
JPS5929667A (ja) | 1982-08-13 | 1984-02-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体および強心剤 |
US4478834A (en) | 1983-02-11 | 1984-10-23 | Usv Pharmaceutical Corporation | Dihydropyridines and their use in the treatment of asthma |
GB8402740D0 (en) | 1984-02-02 | 1984-03-07 | Scras | Furo-(3 4-c)-pyridine derivatives |
JPS6140236A (ja) | 1984-08-02 | 1986-02-26 | Yamanouchi Pharmaceut Co Ltd | ハイドロキノン誘導体 |
DE3431004A1 (de) | 1984-08-23 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung |
GB8603475D0 (en) | 1986-02-12 | 1986-03-19 | Glaxo Group Ltd | Chemical compounds |
DK111387A (da) | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
US4831041A (en) | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
JPH07121937B2 (ja) | 1987-03-18 | 1995-12-25 | 大塚製薬株式会社 | カルボスチリル誘導体 |
JPS63258463A (ja) * | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | 2−フエノキシピリミジン誘導体及び除草剤 |
GB8711802D0 (en) | 1987-05-19 | 1987-06-24 | Fujisawa Pharmaceutical Co | Dithioacetal compounds |
GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
JP2650038B2 (ja) | 1988-01-27 | 1997-09-03 | サントリー株式会社 | ピロリチジン化合物およびその用途 |
JPH01305081A (ja) | 1988-04-04 | 1989-12-08 | E R Squibb & Sons Inc | 3―アシルアミノ―1―[[[(置換スルホニル)アミノ〕カルボニル〕アミノ〕―2―アゼチジノン類 |
US4952574A (en) | 1988-09-26 | 1990-08-28 | Riker Laboratories, Inc. | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides |
IE81170B1 (en) | 1988-10-21 | 2000-05-31 | Zeneca Ltd | Pyridine derivatives |
US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
IT1230859B (it) | 1989-06-05 | 1991-11-08 | Corvi Camillo Spa | 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
JPH05503517A (ja) | 1989-12-18 | 1993-06-10 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンド及びその用途 |
GB2244054B (en) | 1990-04-19 | 1994-04-06 | Ici Plc | Pyridine derivatives |
AU641769B2 (en) | 1990-06-18 | 1993-09-30 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
US5399566A (en) | 1990-06-19 | 1995-03-21 | Meiji Seika Kabushiki Kaisha | Pyridine derivatives having angiotensin II antagonism |
NL9001752A (nl) | 1990-08-02 | 1992-03-02 | Cedona Pharm Bv | Nieuwe 1,4-dihydropyridinederivaten. |
IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
US5403816A (en) | 1990-10-25 | 1995-04-04 | Kumiai Chemical Industry Co., Ltd. | Picolinic acid derivative and herbicidal composition |
JPH05301872A (ja) | 1992-04-23 | 1993-11-16 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
WO1992013841A1 (de) | 1991-02-08 | 1992-08-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Komplexbildner |
JPH0641118A (ja) | 1991-05-31 | 1994-02-15 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
US5185251A (en) | 1991-06-07 | 1993-02-09 | Merck & Co., Inc. | Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559 |
JPH06509069A (ja) | 1991-06-27 | 1994-10-13 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンドおよびその用途 |
JP2600644B2 (ja) | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5202243A (en) | 1991-10-04 | 1993-04-13 | Merck & Co., Inc. | Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices |
GB9203798D0 (en) | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
AU4562693A (en) | 1992-07-01 | 1994-01-31 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Contrast agents for mr diagnosis |
US5290941A (en) | 1992-10-14 | 1994-03-01 | Merck & Co., Inc. | Facile condensation of methylbenzoxazoles with aromatic aldehydes |
US5521202A (en) | 1993-04-07 | 1996-05-28 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivatives and pharmaceutical compositions containing the same |
DE4318550A1 (de) | 1993-06-04 | 1994-12-08 | Boehringer Mannheim Gmbh | Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
AU672699B2 (en) | 1993-06-30 | 1996-10-10 | Sankyo Company Limited | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
JPH0725882A (ja) | 1993-07-07 | 1995-01-27 | Res Dev Corp Of Japan | アクロメリン酸bおよびeを製造するための中間体と、その製造方法 |
DE69418789T2 (de) | 1993-08-05 | 1999-12-02 | Hoechst Marion Roussel Inc | 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren |
EP0640609A1 (en) | 1993-08-24 | 1995-03-01 | Ono Pharmaceutical Co., Ltd. | Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
WO1995014015A1 (en) | 1993-11-19 | 1995-05-26 | Ciba-Geigy Ag | Benzothiophene derivatives possessing a methoxyimino substituent as microbicides |
EP0658559A1 (de) * | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
WO1995021854A1 (en) | 1994-02-14 | 1995-08-17 | Merrell Pharmaceuticals Inc. | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace |
TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
DE4442050A1 (de) | 1994-11-25 | 1996-05-30 | Hoechst Ag | Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien |
US5650408A (en) | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
EP0862435A4 (en) | 1995-11-22 | 1999-02-03 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
JP3895404B2 (ja) | 1996-05-17 | 2007-03-22 | 興和株式会社 | カルコン誘導体及びこれを含有する医薬 |
WO1997041120A1 (en) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
JP2000516958A (ja) | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | ホスホリパーゼ酵素の阻害剤 |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
WO1998009967A1 (fr) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
BR9713027A (pt) | 1996-11-12 | 2000-01-25 | Novartis Ag | Derivados de pirazol úteis como herbicidas |
US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
FR2761069A1 (fr) | 1997-03-20 | 1998-09-25 | Pf Medicament | Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments |
FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
US5760232A (en) | 1997-06-16 | 1998-06-02 | Schering Corporation | Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds |
US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
CA2306312A1 (en) | 1997-10-17 | 1999-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6103723A (en) | 1997-10-17 | 2000-08-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
AU1723099A (en) | 1997-12-12 | 1999-07-05 | Euro-Celtique S.A. | 3-substituted adenines via2-thioxanthines |
EP1062216A1 (en) | 1998-02-25 | 2000-12-27 | Genetics Institute, Inc. | Inhibitors of phospholipase a2 |
JP2002506873A (ja) | 1998-03-18 | 2002-03-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 複素環式シグナル伝達阻害剤、それを含む組成物 |
US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
CN1303376A (zh) | 1998-03-31 | 2001-07-11 | 阿卡蒂亚药品公司 | 对毒蕈碱性受体具有活性的化合物 |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
GB9810860D0 (en) | 1998-05-20 | 1998-07-22 | Hoechst Schering Agrevo Gmbh | Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides |
EP1090009A2 (en) | 1998-06-04 | 2001-04-11 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
HUP0104421A3 (en) | 1998-12-14 | 2003-05-28 | Hoffmann La Roche | Phenylglycine derivatives |
US6544980B2 (en) | 1998-12-31 | 2003-04-08 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
CA2358955A1 (en) | 1998-12-31 | 2000-07-13 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
EP1150955A2 (en) | 1999-02-04 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
AU4397200A (en) | 1999-03-31 | 2000-10-16 | Basf Aktiengesellschaft | Pyridine-2,3-dicarboxylic acid diamides |
JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | N−置換ピペリジン誘導体 |
US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
PT1177176E (pt) | 1999-04-28 | 2006-08-31 | Aventis Pharma Gmbh | Derivados de acidos triarilicos como ligandos de receptores ppar. |
CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
US6184228B1 (en) | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
AU778218B2 (en) | 1999-06-28 | 2004-11-25 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
EP1217001B1 (en) | 1999-09-28 | 2005-12-07 | Eisai Co., Ltd. | Quinuclidine compounds and drugs containing the same as the active ingredient |
SE9903759D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | Pharmaceutically active compounds |
WO2001032130A2 (en) | 1999-11-05 | 2001-05-10 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
AUPQ407699A0 (en) | 1999-11-16 | 1999-12-09 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
WO2001057044A1 (fr) | 2000-02-01 | 2001-08-09 | Daiichi Pharmaceutical Co., Ltd. | Derives de pyrido-oxazine |
FR2804431A1 (fr) | 2000-02-02 | 2001-08-03 | Adir | Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6506755B2 (en) | 2000-02-03 | 2003-01-14 | Hoffmann-La Roche Inc. | Thiazolidinecarboxyl acids |
AUPQ585000A0 (en) | 2000-02-28 | 2000-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
US6559140B2 (en) | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
IL151517A0 (en) | 2000-03-09 | 2003-04-10 | Aventis Pharma Gmbh | Therapeutic uses of ppar mediators |
EP1265840A2 (en) | 2000-03-17 | 2002-12-18 | Corixa Corporation | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
SI1303490T1 (sl) | 2000-07-14 | 2008-10-31 | Hoffmann La Roche | N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov |
AU2001281071A1 (en) | 2000-08-01 | 2002-02-13 | Gmp Companies, Inc. | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
CA2419027A1 (en) | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | Bicyclic compounds as h3 receptor ligands |
US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
AUPR034000A0 (en) | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
DE60142355D1 (de) | 2000-11-20 | 2010-07-22 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JPWO2002051849A1 (ja) | 2000-12-26 | 2004-04-22 | 第一製薬株式会社 | Cdk4活性阻害剤 |
WO2002053547A1 (fr) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Derives d'acide alcanoique, procede de production et utilisation correspondants |
EP1351936A1 (en) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
US20030022923A1 (en) | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
SE0101324D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New process |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
WO2003009807A2 (en) | 2001-07-23 | 2003-02-06 | Galileo Laboratories, Inc. | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
JP2003075970A (ja) | 2001-08-31 | 2003-03-12 | Konica Corp | ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法 |
KR100467313B1 (ko) | 2001-11-22 | 2005-01-24 | 한국전자통신연구원 | 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자 |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
HUP0500165A2 (en) | 2001-12-19 | 2006-09-28 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
US20030190333A1 (en) | 2002-02-04 | 2003-10-09 | Corixa Corporation | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
DE60321775D1 (de) | 2002-04-03 | 2008-08-07 | Topotarget Uk Ltd | Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren |
EP1542704A1 (en) | 2002-04-18 | 2005-06-22 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
CA2493908A1 (en) * | 2002-08-08 | 2004-02-19 | Smithkline Beecham Corporation | Thiophene compounds |
EP1536790A2 (en) | 2002-08-09 | 2005-06-08 | AstraZeneca AB | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
MXPA05001590A (es) | 2002-08-09 | 2005-05-23 | Astrazeneca Ab | Compuestos que tienen actividad en los receptores metabotropicos de glutamato. |
TW200420542A (en) | 2002-08-23 | 2004-10-16 | Kirin Brewery | A compound having TGF β inhibition activity and a medicinal composition containing the same |
US7368578B2 (en) | 2002-09-10 | 2008-05-06 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
GB0223712D0 (en) | 2002-10-14 | 2002-11-20 | Astrazeneca Ab | Chemical intermediate |
AU2003296022B2 (en) | 2002-12-04 | 2007-01-25 | Virginia Commonwealth University | Anti-sickling agents |
US6908921B2 (en) | 2002-12-13 | 2005-06-21 | Merck & Co., Inc. | Quinoxalinone derivatives as bradykinin B1 antagonists |
WO2004056727A2 (en) | 2002-12-19 | 2004-07-08 | Atherogenics, Inc. | Process of making chalcone derivatives |
CA2509835A1 (en) | 2002-12-25 | 2004-07-15 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof |
EP1596818B1 (de) | 2003-02-24 | 2006-05-03 | Randolph Dr. Dr. Prof. Riemschneider | Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung |
GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
US20040186077A1 (en) | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
WO2004089410A1 (ja) | 2003-04-03 | 2004-10-21 | Kyowa Hakko Kogyo Co., Ltd. | 神経因性疼痛の予防及び/または治療剤 |
GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
SI1618092T1 (sl) | 2003-05-01 | 2010-11-30 | Bristol Myers Squibb Co | Aril substituirane pirazolamidne spojine uporabnekot kinazni inhibitorji |
WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
KR20060017791A (ko) | 2003-06-12 | 2006-02-27 | 노보 노르디스크 에이/에스 | 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트 |
WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7211671B2 (en) | 2003-10-01 | 2007-05-01 | Bristol Myers Squibb Company | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
WO2005040119A1 (en) | 2003-10-01 | 2005-05-06 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
WO2005042491A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
EP1682486A1 (en) | 2003-10-31 | 2006-07-26 | Lica Pharmaceuticals A/S | Quaternary amino-functional chalcones |
RU2374230C2 (ru) | 2003-11-05 | 2009-11-27 | Ф.Хоффманн-Ля Рош Аг | Фенильные производные в качестве ppar агонистов |
WO2005047249A1 (en) | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
AU2004296765B2 (en) | 2003-12-02 | 2011-03-24 | Celgene Corporation | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
EP1555264A1 (en) | 2004-01-15 | 2005-07-20 | Sireen AG | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. |
US7378439B2 (en) | 2004-01-20 | 2008-05-27 | Usv, Ltd. | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride |
CA2554120A1 (en) | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
BRPI0508550A (pt) | 2004-03-08 | 2007-08-14 | Wyeth Corp | moduladores de canal de ìon |
WO2005086836A2 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
JP2007528379A (ja) | 2004-03-09 | 2007-10-11 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Hivインテグラーゼ阻害薬 |
US20080132458A1 (en) | 2004-03-10 | 2008-06-05 | Threshold Pharmaceuticals, Inc. | Hypoxia-Activated Anti-Cancer Agents |
DE102004015226B3 (de) | 2004-03-24 | 2005-08-25 | Siemens Ag | Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung |
US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
US20080146585A1 (en) | 2004-04-20 | 2008-06-19 | Ab Science | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy |
EP1745012A4 (en) * | 2004-04-22 | 2010-11-03 | Univ Virginia Commonwealth | COMPOSITIONS OF ALLOSTERIC HEMOGLOBIN MODIFYING SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF |
WO2005102346A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating fibrosis |
JP2007533731A (ja) | 2004-04-23 | 2007-11-22 | アブ サイエンス | マラリア原虫関連の疾病を処置するためのc−kit阻害剤の使用法 |
WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
WO2005112920A1 (en) | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
WO2006003923A1 (ja) | 2004-06-30 | 2006-01-12 | Sankyo Company, Limited | 置換ベンゼン化合物 |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
AU2005304220A1 (en) | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
JP2008523139A (ja) | 2004-12-14 | 2008-07-03 | アストラゼネカ・アクチエボラーグ | 置換アミノピリジン類及びその使用 |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
JP5317257B2 (ja) | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
CA2601871A1 (en) | 2005-03-19 | 2006-09-28 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
WO2006106711A1 (ja) | 2005-03-30 | 2006-10-12 | Eisai R & D Management Co., Ltd. | ピリジン誘導体を含有する抗真菌剤 |
GB0506677D0 (en) | 2005-04-01 | 2005-05-11 | Btg Int Ltd | Iron modulators |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
JP2006306926A (ja) | 2005-04-26 | 2006-11-09 | Fuji Photo Film Co Ltd | 液晶組成物及び液晶素子 |
LT3372281T (lt) | 2005-04-28 | 2021-12-10 | Viiv Healthcare Company | Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą |
JP2008542352A (ja) | 2005-06-01 | 2008-11-27 | ビオアリアンス ファルマ | キノリン化合物及び他のhiv感染治療薬を含む相乗作用のコンビネーション |
US8017635B2 (en) | 2005-06-02 | 2011-09-13 | Fmc Corporation | Phenylalkyl substituted heteroaryl derivatives |
DE102005025989A1 (de) | 2005-06-07 | 2007-01-11 | Bayer Cropscience Ag | Carboxamide |
JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
US20080200673A1 (en) | 2005-06-20 | 2008-08-21 | Astrazeneca Ab | Process for The Preparation of Sulfonic Acid Salts of Oxabispidines |
JP2008545009A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
CN100562514C (zh) * | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
GB0516270D0 (en) | 2005-08-08 | 2005-09-14 | Glaxo Group Ltd | Novel compounds |
JP5162460B2 (ja) | 2005-09-16 | 2013-03-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンゾ[e][1,2,4]トリアゼピン−2−オン誘導体の製造方法 |
ATE539069T1 (de) | 2005-10-11 | 2012-01-15 | Univ Pittsburgh | Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine |
TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
WO2007081630A2 (en) | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
WO2007084914A2 (en) | 2006-01-17 | 2007-07-26 | Neurocrine Biosciences, Inc. | Phenoxy-substituted pyrimidines as adenosine receptor antagonists |
WO2007095495A2 (en) | 2006-02-13 | 2007-08-23 | Pharmacopeia, Inc. | Benzodiazepine gcnf modulators for stem cell modulation |
AU2007214434B2 (en) | 2006-02-15 | 2012-06-14 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
US8013153B2 (en) | 2006-03-23 | 2011-09-06 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US7351434B2 (en) | 2006-04-07 | 2008-04-01 | Academia Sinica | Therapeutic Gastrodia extracts |
RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
CN101466708A (zh) | 2006-04-13 | 2009-06-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的噻吩甲酰胺 |
JP4963863B2 (ja) | 2006-04-27 | 2012-06-27 | 株式会社Adeka | 新規化合物及び該化合物を含有してなる液晶組成物 |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
ES2498043T3 (es) | 2006-06-06 | 2014-09-24 | Cornerstone Therapeutics Inc. | Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas |
WO2007141318A1 (en) | 2006-06-08 | 2007-12-13 | Speedel Experimenta Ag | 2,5-disubstituted piperidines |
GB0614586D0 (en) | 2006-07-22 | 2006-08-30 | Pliva Istrazivacki Inst D O O | Pharmaceutical Formulation |
CN101113148A (zh) | 2006-07-26 | 2008-01-30 | 中国海洋大学 | 二氧哌嗪类化合物及其制备方法和用途 |
AR063211A1 (es) | 2006-07-27 | 2009-01-14 | Amorepacific Corp | Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide. |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
ES2670407T3 (es) | 2006-09-03 | 2018-05-30 | Techfields Biochem Co. Ltd | Profármacos de acetaminofén solubles en agua cargados positivamente y compuestos relacionados con una tasa de penetración de la piel muy rápida |
CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
KR20090068345A (ko) | 2006-10-23 | 2009-06-26 | 머크 앤드 캄파니 인코포레이티드 | 글루코코르티코이드 수용체 리간드로서의 2-[1-페닐-5-하이드록시-4알파-메틸-헥사하이드로사이클로펜타[f]인다졸-5-일]에틸 페닐 유도체 |
JP5246779B2 (ja) | 2006-11-30 | 2013-07-24 | 国立大学法人東京工業大学 | 新規クルクミン誘導体 |
TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
FR2909379B1 (fr) | 2006-11-30 | 2009-01-16 | Servier Lab | Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
DE102006060598A1 (de) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
CA2674946A1 (en) | 2007-01-11 | 2008-07-24 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
US8557853B2 (en) | 2007-02-09 | 2013-10-15 | Allergan, Inc. | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents |
RU2487119C2 (ru) | 2007-02-22 | 2013-07-10 | Зингента Партисипейшнс Аг | Производные иминопиридина и их применение в качестве микробиоцидов |
TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽b2受體調節劑 |
WO2008121066A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors |
CN101679172B (zh) | 2007-05-22 | 2013-05-29 | 住友化学株式会社 | 苯甲醛化合物的制造方法 |
EP2167464B1 (en) | 2007-05-25 | 2014-12-03 | AbbVie Deutschland GmbH & Co KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
JP5189165B2 (ja) | 2007-07-17 | 2013-04-24 | エフ.ホフマン−ラ ロシュ アーゲー | 11β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤 |
AU2008280135B2 (en) | 2007-07-26 | 2012-02-23 | Novartis Ag | Organic compounds |
TW200918521A (en) | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
JP5456681B2 (ja) | 2007-10-17 | 2014-04-02 | ノバルティス アーゲー | ALK阻害剤として有用なイミダゾ[1,2−a]ピリジン誘導体 |
JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
AU2008333326B2 (en) | 2007-12-04 | 2013-05-30 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
JP2009203230A (ja) | 2008-01-31 | 2009-09-10 | Daiichi Sankyo Co Ltd | ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物 |
CA2716514A1 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
WO2009106599A2 (en) | 2008-02-29 | 2009-09-03 | Novartis Ag | Substituted piperidines as therapeutic compounds |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
JPWO2009125606A1 (ja) | 2008-04-11 | 2011-08-04 | 株式会社医薬分子設計研究所 | Pai−1阻害剤 |
US8633245B2 (en) | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
AU2009236256B9 (en) | 2008-04-14 | 2015-09-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
JP2011136906A (ja) | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
JP5436544B2 (ja) * | 2008-05-08 | 2014-03-05 | ノヴァ サウスイースタン ユニバーシティ− | 血管内皮増殖因子受容体に特異的な阻害剤 |
EP2300433A4 (en) | 2008-06-04 | 2012-03-07 | Ambrilia Biopharma Inc | INHIBITORS OF HIV INTEGRASE FROM PYRIDOXINE |
DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
JP5314330B2 (ja) | 2008-06-16 | 2013-10-16 | 住友化学株式会社 | 2−(アリールオキシメチル)ベンズアルデヒドの製造方法およびその中間体 |
GB0811451D0 (en) * | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
US8618300B2 (en) | 2008-09-04 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Indolizine inhibitors of leukotriene production |
JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
US8361959B2 (en) | 2008-10-03 | 2013-01-29 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
DK3135672T3 (da) | 2008-10-10 | 2020-05-04 | Vm Discovery Inc | Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
AU2009314631B2 (en) | 2008-11-12 | 2014-07-31 | Takeda Pharmaceutical Company Limited | Pyrazinopyrazines and derivatives as kinase inhibitors |
WO2010056631A1 (en) | 2008-11-12 | 2010-05-20 | Schering Corporation | Inhibitors of fatty acid binding protein (fabp) |
KR20110097932A (ko) | 2008-12-08 | 2011-08-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 화합물 |
WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
MY157017A (en) | 2009-01-12 | 2016-04-15 | Pfizer Ltd | Sulfonamide derivatives |
US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
TW201033201A (en) * | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
TWI482769B (zh) | 2009-03-16 | 2015-05-01 | Sumitomo Chemical Co | 化合物、光學膜片及光學膜片之製造方法 |
JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
HUE049450T2 (hu) | 2009-03-31 | 2020-09-28 | Ligand Pharm Inc | Endotelin és angiotenzin II receptor antagonista bifenilszulfonamid glomeruloszklerózis és IgA által kiváltott nefropátia kezelésére |
US8367654B2 (en) | 2009-05-08 | 2013-02-05 | Tetraphase Pharmaceuticals, Inc. | 8-AZA tetracycline compounds |
JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
EP2471789B9 (en) | 2009-08-26 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
JPWO2011025006A1 (ja) | 2009-08-31 | 2013-01-31 | 日本ケミファ株式会社 | Gpr119作動薬 |
CA2773561A1 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
SI2498756T2 (sl) | 2009-11-09 | 2023-04-28 | Wyeth Llc | Tabletne formulacije neratinib maleata |
TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
RU2012136457A (ru) | 2010-01-25 | 2014-03-10 | Кареус Терапьютикс Са | Новые композиции для уменьшения аb 42 синтеза и их применение в лечении болезни альцгеймера (ad) |
US20130196960A1 (en) | 2010-02-09 | 2013-08-01 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Receptor Agonists |
US20130178453A1 (en) | 2010-02-09 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Agonists |
JP5375644B2 (ja) | 2010-02-10 | 2013-12-25 | 住友化学株式会社 | 組成物及び光学フィルム |
US20130012434A1 (en) | 2010-03-25 | 2013-01-10 | Wong Michael K | Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
KR101698153B1 (ko) | 2010-04-26 | 2017-01-23 | 광주과학기술원 | P2x1 및 p2x3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
CN102232949A (zh) | 2010-04-27 | 2011-11-09 | 孙远 | 提高药物溶出度的组合物及其制备方法 |
TWI535442B (zh) | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
AU2011258217B2 (en) | 2010-05-26 | 2016-12-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
JP5703594B2 (ja) | 2010-05-26 | 2015-04-22 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
US20130116231A1 (en) | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
MX2013002895A (es) | 2010-09-14 | 2013-06-05 | Inst Biochemii I Biofizyki Pan | Compuestos como moduladores de una proteina cftr mutante y su uso para tratar enfermedades asociadas con las deficiencias de la proteina cftr. |
CN102116772B (zh) | 2010-09-28 | 2013-08-28 | 上海大学 | 二氢查尔酮化合物的筛选方法 |
BR112013009590B8 (pt) | 2010-10-21 | 2019-03-19 | Bayer Ip Gmbh | composto, composição fungicida e método |
UA109457C2 (ru) | 2010-10-21 | 2015-08-25 | Байєр Інтелекчуал Проперті Гмбх | 1-(гетероциклический карбонил)-2-замещенные пирролидины |
JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
CA2823166C (en) | 2010-12-27 | 2019-04-09 | Takeda Pharmaceutical Company Limited | Orally disintegrating tablet |
WO2012097013A1 (en) | 2011-01-10 | 2012-07-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
EP2670245B1 (en) | 2011-02-04 | 2015-09-09 | The Scripps Research Institute | Alpha-ketoheterocycles and methods of making and using |
WO2012138981A2 (en) | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
EP2698368B1 (en) | 2011-04-11 | 2018-02-14 | Green Tech Co., Ltd. | Novel pyrazole derivative |
WO2012143796A2 (en) | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
CN103827091B (zh) | 2011-07-01 | 2016-05-18 | 默克专利有限公司 | 二氢吡唑、其药物组合物及其治疗生育障碍的用途 |
TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CN103874690B (zh) | 2011-07-29 | 2016-07-06 | 卡尔约药物治疗公司 | 含酰肼的核运输调节剂及其用途 |
AU2012308274B2 (en) | 2011-09-15 | 2017-08-17 | Demerx, Inc. | Noribogaine salt ansolvates |
US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
CA2860323C (en) | 2011-12-28 | 2022-03-08 | The Regents Of The University Of California | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US9212190B2 (en) | 2012-01-10 | 2015-12-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
KR20150030709A (ko) | 2012-06-14 | 2015-03-20 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화 |
WO2013192517A2 (en) | 2012-06-21 | 2013-12-27 | Whitehead Institute For Biomedical Research | Compounds for treating infectious diseases |
JP2014005380A (ja) | 2012-06-25 | 2014-01-16 | Dic Corp | 液晶組成物 |
CA2878040A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2014011911A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CA2880178C (en) | 2012-07-27 | 2021-10-26 | Sato Pharmaceutical Co., Ltd. | Difluoromethylene compound |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
EP2888253A4 (en) | 2012-08-24 | 2016-01-06 | Univ Texas | HETEROCYCLIC MODULATORS OF HIF FACTOR ACTIVITY USED FOR THE TREATMENT OF DISEASES |
HUE040025T2 (hu) | 2012-08-24 | 2019-02-28 | Univ Texas | A HIF aktivitás heterociklusos modulátorai betegség kezelésére |
TW201416348A (zh) | 2012-08-29 | 2014-05-01 | Gruenenthal Chemie | 以氟甲基取代之吡咯甲醯胺 |
CN107501413A (zh) | 2012-09-27 | 2017-12-22 | 中外制药株式会社 | Fgfr3融合基因和以其作为标靶的药物 |
WO2014104384A1 (ja) | 2012-12-27 | 2014-07-03 | 住友化学株式会社 | テトラゾリノン化合物及びその用途 |
US9073946B2 (en) | 2013-01-15 | 2015-07-07 | Kineta, Inc. | Anti-viral compounds |
WO2014130856A2 (en) | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Treatment of skeletal-related disorders |
US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
WO2014150256A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
US8952171B2 (en) * | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN105209469A (zh) | 2013-03-15 | 2015-12-30 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
AU2014237348C1 (en) | 2013-03-15 | 2019-02-07 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
ES2710380T3 (es) | 2013-03-15 | 2019-04-24 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
KR20140127587A (ko) | 2013-04-25 | 2014-11-04 | (주)프론트바이오 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
US20160108031A1 (en) | 2013-04-30 | 2016-04-21 | Heinrich-Heine-Universitat Dusseldorf | Inhibitors of nhr2 and/or runx1/eto-tetramerization |
WO2014194201A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
WO2014194242A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Flt3 inhibitors and uses thereof |
US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
WO2015031285A1 (en) | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
US9920073B2 (en) | 2013-10-04 | 2018-03-20 | Drexel University | Compositions useful for inhibiting HIV-1 infection and methods using same |
CN105659121B (zh) | 2013-10-21 | 2019-04-30 | 默克专利股份有限公司 | 制备双折射聚合物膜的方法 |
US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
CN103936658B (zh) | 2013-12-12 | 2016-01-13 | 石家庄诚志永华显示材料有限公司 | 含有咔唑结构单元的化合物及其制备方法与应用 |
CN103936659B (zh) | 2013-12-12 | 2016-06-22 | 石家庄诚志永华显示材料有限公司 | 含有碳桥联咔唑结构单元的化合物及其制备方法与应用 |
EP2883934B1 (en) | 2013-12-16 | 2019-11-13 | Merck Patent GmbH | Liquid-crystalline medium |
US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
MY189995A (en) | 2014-02-07 | 2022-03-22 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
EP3110420B8 (en) | 2014-02-25 | 2019-07-10 | Board of Regents, The University of Texas System | Salts of heterocyclic modulators of hif activity for treatment of disease |
KR101920472B1 (ko) | 2014-03-06 | 2019-02-08 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | 오렉신 수용체 길항제로서의 피페리딘 유도체 |
US20150258106A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse |
US20150258104A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Use of noribogaine for the treatment of pain |
US20150258105A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of alcohol dependence |
TWI648282B (zh) | 2014-03-27 | 2019-01-21 | 印度商托仁特生技有限公司 | 新熔合咪唑苯并噻唑化合物 |
PL3157920T3 (pl) | 2014-06-17 | 2020-02-28 | Chiesi Farmaceutici S.P.A. | Pochodne indolizynowe jako inhibitory kinaz fosfoinozytydu 3 |
WO2016043849A2 (en) | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
DE102015008172A1 (de) | 2014-07-28 | 2016-01-28 | Merck Patent Gmbh | Flüssigkristalline Medien mit homöotroper Ausrichtung |
EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
KR102474637B1 (ko) | 2014-09-30 | 2022-12-05 | 트랜지션즈 옵티칼 인코포레이티드 | 자외선 광 흡수제 |
WO2016057713A1 (en) | 2014-10-07 | 2016-04-14 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
WO2016077541A1 (en) | 2014-11-12 | 2016-05-19 | The Trustees Of The University Of Pennsylvania | Novel anti-infective compounds and methods using same |
EP3223906B1 (en) | 2014-11-26 | 2021-01-06 | DemeRx, Inc. | Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids |
EP3258925B1 (en) | 2015-02-19 | 2023-03-29 | Purdue Pharma LP | Methods and compositions for decreasing gastric emptying |
WO2016149248A1 (en) | 2015-03-15 | 2016-09-22 | Emory University | N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto |
WO2016153951A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | 5-deutero-thiazolidinyldione compounds and methods of treating medical disorders using same |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CN104876912B (zh) | 2015-04-08 | 2017-07-21 | 苏州云轩医药科技有限公司 | Wnt信号通路抑制剂及其应用 |
WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017039318A1 (en) | 2015-09-01 | 2017-03-09 | Kainos Medicine, Inc. | Benzimidazole derivatives for dna methylation inhibitors |
US11124483B2 (en) | 2015-09-02 | 2021-09-21 | The Regents Of The University Of California | HER3 ligands and uses thereof |
US10029995B2 (en) | 2015-09-03 | 2018-07-24 | Forma Therapeutics, Inc. | [6,6] fused bicyclic HDAC8 inhibitors |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
EP4219449A3 (en) | 2016-03-16 | 2023-10-11 | Kura Oncology, Inc. | Substituted indole derivatives and methods of preparation thereof |
WO2017184531A1 (en) | 2016-04-18 | 2017-10-26 | Demerx, Inc. | Treatment of movement-related disorders using noribogaine |
TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
EP3484858A4 (en) | 2016-06-21 | 2020-02-26 | The University of Melbourne | HIV LATENCY ACTIVATORS |
US11746097B2 (en) | 2016-06-24 | 2023-09-05 | Saint Louis University | LXR inverse agonists for treatment of cancer |
TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
MD3880654T2 (ro) | 2018-11-19 | 2022-05-31 | Global Blood Therapeutics Inc | Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei |
-
2014
- 2014-03-10 US US14/776,726 patent/US20160083343A1/en not_active Abandoned
- 2014-03-10 KR KR1020157024781A patent/KR102280614B1/ko active IP Right Grant
- 2014-03-10 CA CA2903220A patent/CA2903220C/en active Active
- 2014-03-10 JP JP2016501058A patent/JP6426694B2/ja active Active
- 2014-03-10 EA EA201591432A patent/EA034922B1/ru unknown
- 2014-03-10 CN CN201480015944.4A patent/CN105073728A/zh not_active Withdrawn
- 2014-03-10 MX MX2015011445A patent/MX2015011445A/es unknown
- 2014-03-10 CN CN202010996640.8A patent/CN112500338A/zh active Pending
- 2014-03-10 MY MYPI2015002271A patent/MY191087A/en unknown
- 2014-03-10 EP EP14770695.6A patent/EP2970196B1/en active Active
- 2014-03-10 SG SG11201507320QA patent/SG11201507320QA/en unknown
- 2014-03-10 AU AU2014237340A patent/AU2014237340C1/en active Active
- 2014-03-10 WO PCT/US2014/022769 patent/WO2014150268A1/en active Application Filing
- 2014-03-10 PE PE2015001922A patent/PE20161035A1/es unknown
- 2014-03-10 ES ES14770695T patent/ES2852054T3/es active Active
- 2014-03-10 AP AP2015008721A patent/AP2015008721A0/xx unknown
- 2014-03-10 BR BR112015021985-3A patent/BR112015021985B1/pt active IP Right Grant
- 2014-03-10 SG SG10201802911RA patent/SG10201802911RA/en unknown
- 2014-03-13 UY UY0001035426A patent/UY35426A/es not_active Application Discontinuation
- 2014-03-13 TW TW103109178A patent/TWI695830B/zh active
-
2015
- 2015-09-02 IL IL241060A patent/IL241060B/en unknown
- 2015-09-07 CL CL2015002501A patent/CL2015002501A1/es unknown
- 2015-09-09 SA SA517382253A patent/SA517382253B1/ar unknown
- 2015-09-09 SA SA515361026A patent/SA515361026B1/ar unknown
-
2017
- 2017-06-02 ZA ZA2017/03791A patent/ZA201703791B/en unknown
-
2018
- 2018-09-11 US US16/127,776 patent/US20190010121A1/en not_active Abandoned
- 2018-10-25 JP JP2018200506A patent/JP6690861B2/ja active Active
- 2018-11-06 AU AU2018260808A patent/AU2018260808B2/en active Active
- 2018-11-09 US US16/186,275 patent/US11053195B2/en active Active
-
2020
- 2020-04-07 JP JP2020069169A patent/JP2020105228A/ja active Pending
- 2020-06-12 AU AU2020203882A patent/AU2020203882A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535183A (en) * | 1980-12-18 | 1985-08-13 | Burroughs Wellcome Co. | Pharmaceutical compounds, preparation, use and intermediates therefor and their preparation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6690861B2 (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
US11236109B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10858317B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10450269B1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10266551B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
JP6463327B2 (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
JP6401772B2 (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
OA17480A (en) | Compounds and uses thereof for the modulation of hemoglobin. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210316 |
|
WD01 | Invention patent application deemed withdrawn after publication |